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Abstract 
 
Alpha-thalassemia is an autosomal recessive disorder characterized by microcytic 
hypochromic anemia. The clinical phenotype ranges from asymptomatic carrier to a lethal 
hydrops fetalis syndrome. Alpha-thalassemia is a common disorder worldwide, and is 
especially frequent in the Mediterranean region, Middle East, South East Asia, Africa and 
Indian subcontinent. The molecular basis of α-thalassemia has been addressed by several 
studies from the Mediterranean region but not from Palestine. Therefore, this study aimed 
to investigate the frequency and genotype of α-globin gene mutations (-α3.7, –α4.2, α2-
IVSI-5nt, --MED and αααanti3.7) in a cohort of Palestinian patients with unexplained 
microcytosis. For this purpose, 73 patients’ samples with unexplained microcytosis not 
due to β-thalassemia or iron deficiency as well as 19 neonates’ samples with an MCV <95 
fL, were analyzed. Gap-PCR, DNA sequencing and ARMS PCR were used for detection 
of α-thalassemia mutations common to the Mediterranean region. Of the 73 patient 
samples analyzed, 50.7 % of samples were carrier for at least one of four mutations, -α3.7, 
α2-IVSI-5nt, --MED and αααanti3.7. The –α3.7 and α2-IVSI-5nt mutations were the most 
frequent mutations among the patients’ samples and were found in 48.9 % and 44.7 % of 
the mutant chromosomes. The --MED and αααanti3.7 mutations were found in 4.3 % and 2.1 
% of mutant chromosomes, respectively. In the neonates’ samples, the –α3.7 and α2-IVSI-
5nt mutations were also the most frequent and were found in a frequency close to that 
observed in patients’ samples. The –α4.2 mutation was not detected among the study 
samples, as this mutation is present in low frequency in the Mediterranean region. The 
high frequency of the α2-IVSI-5nt mutation is novel to the Palestinian α-thalassemia 
patients and has not been reported in other populations. Analysis of the correlation 
between red cell parameters and the different α-thalassemia mutations reveled that none of 
these parameters could predict the presence of α-thalassemia mutations. The red cell 
indices are general indicators that are altered in different hemoglobin disorders. In 
conclusion, 50.7 % of the study samples have one or two of the α-thalassemia mutations 
investigated in this study. Molecular diagnosis of α-thalassemia is strongly recommended 
in cases with unexplained microcytosis in Palestine. The –α3.7 and α2-IVSI-5nt mutations 
are the most frequent α-thalassemia mutations among the samples analyzed in this study.  
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Chapter One: Introduction  
 
 
1. Introduction  
 
Hemoglobinopathies are a heterogeneous group of inherited disorders of hemoglobin (Hb) 
characterized by reduced synthesis of one or more globin chains (Thalassemias) or synthesis of 
a structurally abnormal Hb variant (Clark and Thein, 2004). The WHO estimates that about 7 % 
of the world populations are carriers to Hb disorders. The expected number of new cases of 
thalassemia will be around 900,000 in the next 20 years. So it is considered one of the most 
common monogenic diseases and one of the world’s major health problems (Vichinsky, 2005; 
Kohne, 2011).  
  
In the past, thalassemias were mainly found in the Mediterranean area and large parts of Asia 
and Africa. Today due to international migration, thalassemia is found worldwide albeit in 
different frequencies (Kohne, 2011). 
  
1.1. Human Hemoglobins  
 
Hemoglobin is a globular protein that consists of two alpha chains, each with 141 amino acids, 
and two beta chains, each with 146 amino acids. Each α or β globin chain folds into eight α 
helical segments (A-H) which, in turn, fold to form globular structures. The globular structure 
is stabilized by salt bridges, hydrogen bonds, and hydrophobic interactions. The heme group is 
located within a hydrophobic pocket of each globin subunit. (Nelson and Cox, 2004).  
 
There are two types of interactions between α and β chains: α1β1 and α1β2. Each poly peptide 
chain binds to one heme group. The heme group is composed of an iron atom (in the ferrous 
state) positioned in the center of the protoporphyrin ring (Figure 1). Each iron atom binds 
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successfully and reversibly to one oxygen atom transporting it from the lungs to the peripheral 
tissues (Nelson and Cox, 2004; Ribeiro and Sonati, 2008). 
 
All normal hemoglobins are formed as tetramers consisting of two α–like chains and two β-like 
chains. Normal adult RBCs contain the following types of hemoglobin: 95-97% of HbA (α2β2), 
2-3% of HbA2 (α2δ2) and 1-2% of HbF (α2γ2) (Greer et al., 2004; Sarnaik, 2005). 
 
 
 
Figure 1: Hemoglobin structure. (Adapted from Mortada, 2009). 
 
1.2. Nomenclature 
Hemoglobin was named by using the letters of the alphabet, such as HbA for adult hemoglobin, 
HbF for fetal hemoglobin and HbS for sickle cell hemoglobin. By the time, this system was 
unable to provide enough names for new hemoglobins so the need for a new system was 
increased. In 1960, a new system of nomenclature was developed; the alphabets were used only 
for normal hemoglobins A and F and abnormal hemoglobin C, E, S and H (Greer et al., 2004). 
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Abnormal hemoglobins have both a common name which is usually given by the discoverer and 
a scientific name which shows the variant chain, both the sequential and helical number of the 
abnormal amino acid and the nature of substitution, thus HbS is designated as α2β2
6Glu-Val or 
more precisely as α2β2 
6(A3)Glu-Val (Greer et al.,2004). 
 
1.3. Organization and Structure of Globin Genes 
Globin genes occur in clusters, the α- and α-like genes on the short arm of chromosome 16, and 
the β- and β-like genes on the short arm of chromosome 11(Figure 2). The α-like cluster extends 
over 40-kilobase range, and the β-like cluster extends over 60-kilobase range. In the α-gene 
cluster, two α-globin structural genes α1 and α2 are placed at 3R end of the complex. The 
nucleotide sequences of both genes are the same with slight variation in the sequence of second 
intron, but the rate of expression of α2 gene is twice that of α1 gene. Consequently the α2-gene 
mutations are more severe than the α1-gene mutations (Chui, 2005).  
The β gene complex consists of six genes arranged in the following 5R to 3R order: a single 
embryonic gene (ε), two fetal genes (γG  and γA), a pseudo-β gene (ψβ), the δ gene, and the β 
gene. All functional globin genes consist of three exons and two introns (Ribeiro and Sonati, 
2008). 
Each cluster of genes are controlled by regulatory elements located upstream of the genes. The 
β cluster is controlled by a group of remote regulatory elements DNAse I–hypersensitive sites 
collectively known as the locus control region (LCR) (Higgs et al., 2005). Whereas in the α 
cluster, there is a single known element referred to as HS-40,   (so called because it is a DNAse 
I–hypersensitive site located approximately 40 kb upstream of the 5′ end of the ζ-globin gene) 
as shown in Figure 2 (Steensma et al., 2005). 
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Figure 2: α –Globin gene cluster. In the top, the α-like globin cluster which includes the ζ-, α2-, and 
α1-globin genes located on chromosome 16 near the telomeric region, and is controlled by HS-40. In the 
bottom, the β-like globin, located on the short arm of chromosome 11, and is controlled by the locus 
control region (LCR). (Adapted from Higgs et al., 2005). 
 
1.4. Hemoglobin Switching during Development  
Different hemoglobins are produced during development, early in embryogenesis two globin 
genes switches take place, the embryonic to fetal switch (ε to γ  and  ζ to α), which are 
completed at 10 weeks of gestation, and the fetal to adult switch (γ to β) which occurs during the 
prenatal period (Greer et al., 2004). 
During the second and third trimesters, the major hemoglobin is fetal hemoglobin (HbF, α2γ2), 
with approximately 10% HbA. HbF remains the primary hemoglobin throughout most of 
gestation. HbF has a higher oxygen affinity compared to adult Hb (HbA α2β2) (Giambona et al., 
2009) as a result of low interaction with 2,3-DPG, and these properties make the delivery of 
oxygen through placenta easier, giving the fetus better access to oxygen from the mother's 
bloodstream (Mosca et al., 2009). 
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During the third trimester, the production of γ chains decreases, while the synthesis of β chains 
increases. At birth, the γ/β ratio is approximately 2:1, the silencing of the γ gene continues after 
birth until six months of age. After six months, HbA becomes the major hemoglobin with 
around 1% of HbF, and 2-3 % of HbA2 (Giambona et al., 2009). In normal adults, HbF is 
heterogeneously distributed among erythrocytes though its synthesis is restricted to a small 
population of cells, termed F-cells. Approximately 3–7 % of red blood cells are F-cells, 
containing 20–25% of HbF (Mosca et al., 2009). HbA2 (α2δ2) differs from HbA by only 10 
amino acids, but it almost has the same functional properties of HbA. The low level of δ-globin 
gene expression in comparison to β gene may be due to both transcriptional and 
posttranscriptional regulation (Giambona et al., 2009). 
 
1.5 Thalassemia Classification 
 
There are several types of Thalassemia that are usually classified based on the type of globin 
chain affected as α, β, δβ, and γδβ Thalassemia. β-Thalassemia is divided into β+- and β0-
Thalassemia. In the heterozygous state of β-Thalassemia, abnormalities in red cell morphology 
are present, and there is an increase in the amount of HbA2, and variable increase in HbF. The 
homozygous state of β+ Thalassemia is accompanied by severe anemia, due to reduction in the 
synthesis of β-globin chain and therefore HbA(Bank, and Ramirez 1978; Weatherall, 1997; 
Greer et al., 2004). Table 1  shows different genotypes and the related changes in RBC indices, 
hemoglobin pattern, and the condition of anemia associated with β-Thalassemia.  
Other hemoglobin variants may be unstable and cause hemolytic anemia, e.g. Hb Bibba which 
has low oxygen affinity, Hb Titusville with high oxygen affinity and Hb Chesapeake or 
methemoglobin presenting as cyanosis. Rarely, homozygosity for unstable α-chain hemoglobin 
variants such as Hb Taybe can lead to hydrops fetalis (Chui, 2005). 
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Table 1: States of β-Thalassemia and related disorders (Kohne E, 2011) 
Normal Finding Arrangement of β 
-globin genes 
Hb and RBC  
indices 
Hemoglobin 
pattern 
Symptoms  
 
Heterozygous  
β-Thalassemia 
 (β-Thalassemia 
minor) 
β+ 
β0 
Hb ♂ 9 to 15 g/dL 
Hb ♀ 9 to 13 g/dL 
MCV 55 to 75 fL 
MCH 19 to 25 pg 
HbA2 >3.2% 
HbF 0.5 to 6% 
Mild anemia 
Homozygous  
β-Thalassemia 
(β-Thalassemia 
major) 
Compound 
heterozygous 
β-Thalassemia 
(β-Thalassemia 
major) 
β+/β+ 
β0/β0 
β+/β0 
Hb <7 g/dL 
MCV 50 to 60 fL 
MCH 14 to 20 pg 
HbA2 variable 
HbF 70 to 90% 
Severe illness 
with long-
term 
transfusion-
dependent 
anemia 
Mild homozygous 
or compound 
heterozygous  
β-Thalassemia 
(β-Thalassemia 
intermedia) 
β+/β+ 
β+/β0 
β0/β0  influential 
factors 
Hb 6 to 10 g/dL 
MCV 55 to 70 fL 
MCH 15 to 23 pg 
HbA2 variable 
HbF up to 100% 
Moderate 
disease 
variable 
transfusion 
dependence 
 
1.6. α-Thalassemia 
α-Thalassemia is the most common inherited disorder of hemoglobin (Hb) synthesis and 
probably the most common single-gene disorder in the world (Chong et al., 2000; Harteveld and 
Higgs, 2010). The α-thalassaemia is inherited as an autosomal recessive disorder characterized 
by a microcytic hypochromic anemia, and variable clinical picture ranging from asymptomatic 
to a fatal hemolytic anemia (Harteveled and Higgs, 2010). A normal individual usually has four 
α-globin genes. Due to deletions and duplications, the number of α-globin genes in each 
individual can vary from none to as many as eight α-globin genes (Fucharoen and Winichagoon, 
2011). Therefore, serious α-globin gene mutations can have an adverse effect upon fetal 
development, and even cause death in the uterus (Chui and Waye, 1998; Lorey et al., 2001). 
Multiple gene rearrangements with three to six ζ-like embryonic genes have also been reported 
(Felice et al., 1986). 
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1.7. Molecular Basis of α –Thalassemia 
 
Normal individuals have usually four α-globin genes and this genotype is written as αα/αα. The 
α-thalassaemia is caused commonly by deletion of one (-α) or both (--) α-genes on chromosome 
16 (Pirastu et al. 1982; Alcoforado et al. 2012). When a mutation completely removes α-gene 
from a chromosome this is called α0-thalassaemia and when the mutation only partially down 
regulate the expression from the chromosome this is called α+ thalassaemia (Harteveled and 
Higgs, 2010). There are at least 40 different deletion mutations affecting the α-globin genes. 
The size of the deletion is important and affects the clinical phenotype of the disease 
(Vichinsky, 2009). The most common deletion mutations are shown in Table 2. 
 
Table 2: Classification of the deletion α-Thalassemia (Vichinsky, 2009). 
Type of deletion Phenotype 
No. of 
examples 
recorded 
Examples 
Deletion involving one or both α genes  
Deletion of all or part of  one α gene 
α+ Thalassemia 7 -α3.7, -α4.2 
Deletion of all or part of both α genes, 
without deletion of HS-40 
α0 Thalassemia 20 --SEA/, --MED/ 
Deletion of both α genes and of HS-40 α0 Thalassemia 8 --DUTCH11 
Extensive loss of 16p13.3(1-2Mb) 
including both α genes and HS-40 
α0 Thalassemia 
17, with 
mental 
retardation and 
dysmorphism 
--BO 
 
Deletion of α1 gene and 18-20 kb 
downstream of α1 gene 
α0 Thalassemia 1 (α)- ZF* 
Deletion of upstream major regulatory 
element (HS-40) without deletion of 
genes 
α0 or very severe  α+ 
Thalassemia 
12 (αα)RA** 
*(α) indicate that the α-gene is present but non-functional. 
**(αα) indicate that both α-genes are present but non-functional. 
 
Non-deletion types of α-Thalassemia are much less common than deletion α-Thalassemia. The 
clinical picture varies from the Hb Bart’s hydrops fetalis to the silent carrier state.  The most 
common non-deletion mutations are shown in Table 3. The most common non-deletion variants 
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are mapped to the α2-gene (Clark and Thein, 2004). The non-deletional α+ Thalassemias are 
rare and most of the mutations involve the α2 gene, which has a higher expression rate than the 
α1-gene with a ratio around 3:1(Fucharoen and Winichagoon, 2011). 
 
Table 3:  Classification of non-deletional α-Thalassemia (Vichinsky, 2009).  
Examples 
No. of 
examples 
recognized  
Phenotype Type of deletion 
α2 IVS1(-5nt) 3 α
+ Thalassemia 
RNA splice site mutation in α1 or α2 
gene 
α2 
AATAAA→AATAAG 
4 
α+ – α0 
Thalassemia 
RNA polyadenylation signal 
mutations 
α2 ATG→ACG 5 
α+ Thalassemia, 
α+ – α0 
Impaired RNA translation consequent 
on initiation codon or initiation 
consensus sequence mutation 
Codon 30/31 (–4nt) 
frame shift 
5 
α+ or α0 
Thalassemia 
Impaired RNA translation consequent 
on a frame shift or nonsense mutation 
Hemoglobin Constant 
SpringTAA→CAA  
(αCSα) 
5 α+ Thalassemia 
Impaired RNA translation consequent 
on a termination codon mutation 
leading to an elongated mRNA and α 
globin chain 
Hemoglobin Arginia αAgr 
α 
At least 18 α+ Thalassemia 
Production of highly unstable α chain 
as a result of point mutation or a 
small deletion 
ATR-X syndrome  α+ Thalassemia 
Lack of a transactivating factor 
encoded by the ATRX gene 
 
1.8. Clinical and Laboratory Features 
1.8.1. α-Thalassemia: Clinical Forms 
 
α-Thalassemia is the most common hemoglobin  disorder in the world, with high frequencies in 
Southeast Asia, the Middle East, including Iran, as well as the Mediterranean populations 
(Zandian et al., 2008). In α-Thalassemia four clinical pictures are recognized: silent carrier, α-
Thalassemia trait, HbH disease, and Hb Bart hydrops fetalis. Figure 3 shows the classification 
of gene defects and phenotypic expression of these disorders (Harteveld and Higgs, 2010). 
Table 4 shows the clinical picture for α-Thalassemia.   
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Figure 3: Classification of α-globin gene defects and phenotypic expression (Harteveld and 
Higgs, 2010). 
 
I.8.1.1 Silent Carrier 
This condition results from the presence of a single α-globin gene defect, such as 3.7 and 4.2-kb 
deletions (designated as -α3.7/αα and –α4.2/αα, respectively). The rightward 3.7 kb deletion is 
caused by reciprocal recombination between Z segments producing a chromosome with only 
one functional α-gene (-α3.7/ or rightward deletion) causing α-Thalassemia and α-triplication 
allele without a thalassemic effect (Figure 4). Likewise a reciprocal recombination between 
mispaired X-boxes results in 4.2 kb deletion, called leftward deletion (-α4.2/) (Harteveld and 
Higgs, 2010). 
This genotype is diagnosed in the newborn period by a very mild increased percentage (1 to 
2%) of Hb Bart, which consists of four γ-globin chains (γ4). Those patients have completely 
silent phenotype (normal RBC indices) or present with a moderate Thalassemia like 
hematological picture, reduced MCV and MCH and very mild anemia with normal HbA2 and 
HbF, and reduced α to β-globin chain synthesis ratio in the range of 0.8 to 0.9 (Greer et al., 
2004).  
  10
 
 
Figure 4: Deletions that cause α
+
-Thalassemia. A cross-over between the misaligned Z boxes during 
meiosis gives rise to the -α3.7 and αααanti 3.7 chromosomes. Cross-over between misaligned X-boxes give 
rise to -α4.2 and αααanti 4.2. Adapted from (Harteveld and Higgs, 2010). 
 
1.8.1.2 α-Thalassemia Trait 
The α-Thalassemia carrier state results from two α-globin genes deletion, either in cis on the 
same chromosome (--/αα, heterozygous α0-Thalassemia) or in trans on opposite chromosome (-
α/-α, homozygous α+ Thalassemia) (Singer, 2009). 
These disorders are easily diagnosed in newborns by the finding of high levels of Hb Barts (5- 6 
%). In adults the clinical picture vary from mild to moderate microcytic hypochromic anemia 
(detected on a routine blood count), normal HbA2 and HbF, and a reduced α to β-globin chain 
synthesis ratio in the range of 0.7 to 0.8 (Greer et al., 2004). 
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1.8.1.3. HbH disease 
 
This condition results from the deletion of three α-globin genes and the presence of only one 
active α-globin gene, usually as a result of the compound heterozygous state for α0 
Thalassemia/α+Thalassemia (--/-α or --/α Tα). Consequentially, the decrease in α-globin chains 
result in an insufficient production of normal HbA (α2β2) and HbA2 (α2δ2) in the adult patient 
and of fetal hemoglobin (HbF, α2γ2) in the fetus and the newborn (Baysal, 2011). Defective α-
globin production results in excess β- and γ-globin chains, each able to form insoluble 
tetramers: γ4 (Hb Bart’s) and β4 (HbH), Which precipitates inside red cells and causes cell 
membrane damage leading to hemolysis and ineffective erythropoiesis. Also these tetramers 
have very high oxygen affinity and are therefore useless for effective oxygen delivery 
(Fucharoen and Viprakasti, 2009; Singer, 2009). 
 
The non-deletional forms of HbH disease (which are considered more severe than deletional 
forms) result from deletion of two α-globin genes plus inactivation of the third α-globin gene by 
non-deletional mutation such as Hb Constant Spring, Pakse, or Quong Sze mutations (Chui, 
2005). Hb Constant Spring is the most common non-deletional α-globin gene mutation 
associated with HbH disease. Seventy five percent of HbH cases are caused by deletion 
mutations (Vichinsky, 2005). The clinical picture of those patients is characterized by 
moderately to severe hemolytic anemia with microcytosis, hypochromia, low HbA2 and HbF 
levels and varying quantities of HbH (2–30%) (Baysal, 2011). 
 
Hemoglobin Constant Spring (CS) the most common non deletional α+-Thalassemia in 
Southeast Asia, is a variant with elongated α-globin chains. HbCS is caused by a point mutation 
in the termination codon of α2-gene that converts it to Glutamine codon (TAA->CAA) and 
results in an elongated α-chain, with extra 31 amino acid residues. The elongated α-chain is 
unstable and is produced at a very limited rate (~1 % of normal level) (Fucharoen and 
Winichagoon, 2011). 
 
Patients with HbH disease usually suffer from hepato- splenomegaly, due to extra-medullary 
haematopoiesis which may be severe (Sarnaik, 2005). Jaundice may be present in variable 
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degrees and children may show growth retardation. Other complications include infections, leg 
ulcers, gall stones, folic acid deficiency and acute hemolytic episodes in response to drugs and 
infections (Harteveld and Higgs, 2010; Kohne, 2011). HbH disease also presents with a 
significant increase in RDW and α/β globin chain ratio in the range of 0.5-0.1 (Villegas et al., 
1998). 
1.8.1.4. Hb Bart's Hydrops Foetalis Syndrome 
Hb Bart's hydrops foetalis syndrome is the most severe clinical condition of α-Thalassemia, and 
results from the deletion of all four α-globin genes, homozygous α0-Thalassemiaor (--/--) 
(Kohne, 2011). A fetus homozygous for α0-Thalassemia produces mainly Hb Barts that has 
high affinity to oxygen that can’t deliver oxygen to tissues and this result in a progressive 
severe anemia. Many of these fetuses survive to the second or even third trimester of gestation 
because of the persistence of embryonic ζ-globin chain production (Chui, 2005; Harteveld and 
Higgs, 2010).  In normal fetus, embryonic hemoglobins are responsible for oxygen deliver in 
the first eight weeks of gestation, those hemoglobins are hemoglobin Gower 1, hemoglobin 
Gower 2, and hemoglobin Portland, after that a switch to fetal hemoglobin (hemoglobin F, 
α2/γ2)  occurs. In Hb Barts syndrome, this switch does not occur due to absence of α-globin 
chains. Since α-globin chains are absent, hemoglobin F cannot be synthesized and hemoglobin 
Bart’s becomes the dominant hemoglobin. This anemia underestimates the severity of hypoxia 
because hemoglobin Bart’s has no hem/hem interaction or Bohr effect and binds oxygen 
irreversibly (Vichinsky, 2009; Harteveld and Higgs, 2010). 
The clinical picture of this syndrome presents with very severe anemia (Hb level range, 3 to 8 
g/dL), with marked hepatosplenomegaly, generalized edema, signs of cardiac failure, and 
extensive extramedullary erythropoiesis (Weatherall and Clegg, 2001). In addition, there are 
maternal complications such as placentomegaly, hypertension and pre-eclampsia, hemorrhage, 
disseminated intravascular coagulation and others that may be life threatening for the mother 
(Chui, 2005). 
Homozygosis for the South East Asian deletion mutation (-α SEA/) is the most common cause of 
hydrops fetalis in that region. While it is the most common deletion mutation in South East 
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Asia, it is also found worldwide among many ethnic groups. The -- MED/ deletion mutation is a 
common α0-Thalassemia mutation in Mediterranean region, particularly Greece and Cyprus. In 
addition to China and Southeast Asia, Hb Bart’s hydrops fetalis is now being recognized in 
Greece, Turkey, Cyprus, India, Sardinia, and other parts of the world (Vichinsky, 2009). 
 
Table 4:  The clinical picture of α-Thalassemia (Kohne, 2011) 
Phenotype Genotype RBCs index Hb pattern Symptoms  
Normal findings αα/αα 
Hb normal, 
MCH normal 
Normal No symptoms 
Heterozygous α+-Thalassemia 
=  Silent α-Thalassemia 
– α/αα 
Hb normal, 
MCH <27 pg 
Normal 
No symptoms 
slight changes to 
blood count 
Homozygous α+-Thalassemia 
= α-Thalassemia trait/minor 
– α/– α 
Hb normal or 
low, 
MCH <26 pg 
Normal 
Mild anemia 
significant 
changes to blood 
count 
Heterozygous α0-Thalassemia 
= α-Thalassemia trait/minor 
– –/αα 
Hb normal or 
low, 
MCH <24 pg 
Normal 
Mild anemia  
significant 
changes to blood 
count 
Mixed heterozygosity, α+/α0-
Thalassemia 
= HbH disease 
– –/– α 
Hb 8 to 10 
g/dL, 
MCH <22 pg 
HbH ≈ 10-
20% 
Variable chronic 
hemolytic anemia 
Homozygous α0-Thalassemia 
= Hb Bart’s hydrops fetalis 
– –/– – 
Hb <6 g/dL, 
MCH <20 pg 
Hb Bart’s 80-
90%, 
Hb Portland ≈ 
10 -20%, 
HbH <1% 
Life-threatening 
fetal anemia  
 
 
1.8.2. Unusual Forms of α-Thalassemia 
There are two unusual forms of α-Thalassemia: acquired HbH disease associated with 
Myelodysplasia Syndromes and α-Thalassemia associated with mental retardation syndrome. 
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1.8.2.1. Acquired HbH Disease Associated with Myelodysplasia 
This condition presents in some patients with Myelodysplasia Syndromes and is characterized 
with severe hypochromic and microcytic anemia, HbH inclusion bodies in RBCs, 
anisopoikilocytosis, and decreased α/ β-globin chain synthesis ratio ( Greer et al., 2004; 
Steensmal et al., 2005). It was noticed that acquired α-Thalassemia is not exclusive to 
Myelodysplasia Syndromes, but it was also reported in other hematological malignancies. The 
exact cause of acquired α-Thalassemia is not known, but some reports linked this disorder to a 
mutation in ATRX gene.  (Steensmal et al., 2005).  The protein encoded by this gene ATRX is 
widely expressed throughout development, which uses the hydrolysis of ATP as a source of 
energy. This protein is frequently present in multi-component complexes that remodel 
chromatin and thereby influence the wide range of the nuclear processes such as DNA 
replication, DNA repair, recombination, transcription and DNA methylation (Higgs et al., 
2005). 
 
1.8.2.2. α-Thalassemia (ATRX) Syndromes 
There are two different syndromes in which α-Thalassemia is associated with mental 
retardation. The first is characterized by relatively mild mental retardation and a variety of 
facial and skeletal abnormalities. This disorder results from 1-2 mega base pairs deletion 
resulting from rearrangements of the short arm of chromosome 16. This condition is called α-
Thalassemia mental retardation -16 syndromes (Harteveld and Higgs, 2010; Greer et al., 2004).  
The second is X-Linked mental retardation (XLMR) syndrome, results from an abnormality in 
the ATRX gene. Clinical diagnosis is based on the presence of mental retardation in 
combination with α-Thalassemia and a characteristic and recognizable facial appearance, 
genital abnormalities, and other abnormalities, and defective α-globin synthesis. This disease is 
rare. About 170 cases have been reported worldwide (Thakur et al., 2011). 
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1.9. Interaction of α-Thalassemia with other Thalassemia and Hemoglobin variants 
The co-inheritance of α-Thalassemia and β-Thalassemia is common in areas where both 
disorders are frequent, and may improve the anemia, and leads to production of red blood cells 
with normal indices (Harteveld and Higgs, 2010). 
The interaction of α-Thalassemia with other hemglobinopathies such as HbS trait is also 
common. Individuals with a full complement of α-globin genes have more than 35 % HbS, 
compared with 28 to 35 % in those with the (-α/αα) genotype, 25 to 30 % in those with the (-α/-
α) genotype, and no more than 20 % in those with the rare (-/-α) genotype (Greer et al., 2004). 
The inheritance of α-Thalassemia and hereditary spherocytosis was also reported, in a patient 
suffering from severe hemolytic anemia, and he was transfusion dependent. In that patient, the 
hemolytic effect of hereditary spherocytosis was not decreased by the effect of hemoglobin H 
disease (in which there is an increase in osmotic resistance), so a severe hypochromic 
normocytic anemia was found (Zuysal et al., 1998). 
 
1.10. Prevalence and Geographic Distribution 
 
The overall distribution of α-Thalassemia is similar to that of β-Thalassemia (Alcoforado et 
al.2012). Approximately, 5 % of the world’s population has a globin gene variant, but only 
1.7%  has α- or β-Thalassemia trait (Muncie and Campbell, 2009). Thalassemia occurs at high 
frequencies throughout all tropical and subtropical regions of the world (Harteveld and Higgs, 
2010). They were originally found mainly in the Mediterranean area and large parts of Asia and 
Africa (Kohne, 2011) with gene frequencies reaching up to 10 % in some South East Asian 
countries (Sae-ung et al., 2007). 
 
The Mediterranean region, certain parts of North and West Africa, Middle East, Indian 
subcontinent, southern Far East, and South East Asia have the highest prevalence of β-
Thalassemia and comprise the so-called “Thalassemia belt”( Elgawhary et al., 2008).  
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The frequency of α-Thalassemia in the Arabian Peninsula is high, particularly in Oman 
(38.9%), followed by UAE nationals (16.5%) and Yemenis (6.5%) (Baysal, 2011). α-
Thalassemia shows an incidence of (4.80 to 5.48%) in Tunisia, (9.0%) in Algeria and (2.2%) in 
Morocco ( Khelil et al., 2010). α-Thalassemia is particularly common in China and Southeast 
Asia, with up to (40% )of the regional population being carriers (Vichinsky, 2009). 
 
The –α3.7/ mutation is the most frequent allele in North Africa. Although it is specific to the 
Mediterranean regions but it reaches its highest frequencies in Iran (79.1%) and Saudi Arabia 
(64%) indicating that it could have been introduced in North Africa by Arab conquests (Khelil 
et al., 2010). 
The gene frequencies of α-Thalassemia reach (30-40 %) in Northern Thailand and Laos, (4.5%) 
in Malaysia and (5 %) in the remote island of the Philippines whereas β-Thalassemia vary 
between (1 and 9 %) (Fucharoen and Winichagoon, 2011). 
HbH disease is predominantly seen in South East Asia, the Middle East and the Mediterranean, 
similarly the Hb Bart's hydrops foetalis syndrome is predominantly seen in South East Asia 
(Harteveld and Higgs, 2010). In addition to China and Southeast Asia, Hb Bart’s hydrops fetalis 
is now being recognized in Greece, Turkey, Cyprus, India, Sardinia, and other parts of the 
world (Vichinsky, 2009). 
 
One of the most frequent α-Thalassemia mutations is the – αSEA/ deletion, which deletes both α-
globin genes but spares the embryonic globin genes (Vichinsky, 2009). The carrier rate for the 
common α-globin gene deletion (-αSEA/) is reported to be (3–14 %) in various areas in Asia, 
including (4.6%) in Northern Thailand, (4.1%) in Hong Kong and (4.1%) in Guangdong 
Province in China (Singer, 2009). 
In Palestine, the frequency of α-Thalassemia as well as other hemoglobinopathies is not known. 
However, Younis et al. (1996) found that the prevalence of β-Thalassemia trait among 
secondary school students in the West Bank is 3.13 %. To our knowledge, until now there is 
only one report that examined the molecular genotypes of α-globin gene mutations in a small 
group of Palestinian Arabs (around 55 patients) living inside Palestine 1948 and all were 
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referred to the clinic for molecular evaluation of anemia including unexplained microcytosis or 
suspected of having α-Thalassemia (Oron-Karni et al., 2000). In the latter report the Palestinian 
Arabs included in this study were unique in having a large proportion of point mutations/small 
deletion (63/109 mutant chromosomes), three of which were found frequently: α2-IVS1-5nt 
(29\109 mutant chromosomes), α1 ∆T39 (22/109 mutant chromosomes) and α2 poly (A) nt 6 
(11/109 mutant chromosomes). The deletion mutations were less frequent than point 
mutations/small deletion in this sample (43/109 mutant chromosomes). The authors reported 
five deletions:  –α3.7/, αααanti3.7, α4.2/, -αMED/ and Multi α-genes; and these deletions were found 
in 30, 6, 1, 5 and 1 chromosomes out of 109  mutant chromosomes analyzed, respectively 
(Oron-Karni et al., 2000).   
Epidemiological surveys suggest that there are approximately 15,000 transfusion-dependent 
subjects in Europe and that more than 6000 of these subjects are in Italy (Giambona et al., 
2009). In Southeast Asia, α-Thalassemia causes HbH disease and Hb Barts hydrops fetalis. 
Fetuses with the devastating Hb Barts hydrops fetalis due to the complete lack of α globin 
genes die in uterus or shortly after birth, often during the second or third trimester (Chui, 2005). 
The prevalence of α-Thalassemia was analyzed in Eastern Sicily (Italy), the results showed six 
different genotypes, the most common (36.6 % of the cases) being the heterozygous state for -
α3.7 kb deletion (-α3.7/αα). The homozygous condition for this defect (-α3.7/-α3.7) had a relative 
frequency of (27.5 %). Ten percent of the individuals were carriers of the --MED/ deletion at the 
heterozygous state --MED/ (Bella et al., 2006). 
In Tunisia, six α-globin gene molecular defects were found to be responsible for α-Thalassemia, 
and the most common mutation was –α3.7 /, then --MED (Siala et al., 2008). In Iran, the deletion 
mutations –α3.7, -α4.2, and --MED were found to be the most common α-globin deletions, and the 
polyadenylation signal mutation α2-poly (A) (AATAAA>AATGAA) was the most common 
point mutation (Tamaddoni, 2009).  
It seems that each region has its unique spectrum of abnormal Hbs and Thalassemia (α- and β-
Thalassemia as well as other types of Thalassemia) mutations (Old, 2003). 
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The identification of α-gene mutations is essential for identification of patients and carriers as 
well as in compound heterozygote’s resulting from co-inheritance of α-Thalassemia trait and β-
Thalassemia trait or Hb variants. The molecular diagnosis is of great importance for 
understanding of the genotype/phenotype relationship and will enhance the patient’s 
management and counseling (Old, 2003; Clark and Thein, 2004). 
Since most of the α-Thalassemia are caused by deletion mutations which show regionally and 
ethnic distribution (Chong et al., 2000). Screening for α-Thalassemia has been successfully 
performed with one or two multiplex Gap-PCRs using a combination of primers specific for the 
most common deletions (Old, 2003). Other point mutations have been detected using RFLP-
PCR, ARMS-PCR or DNA sequencing (Oron-Karni et al., 2000; Clark and Thein, 2004). 
In Palestine, the frequency and the molecular genotypes of α-Thalassemia are not known. 
Currently patients diagnosed with microcytosis not due to β-Thalassemia or iron deficiency are 
not investigated further to establish the correct diagnosis. Thus the inappropriate diagnosis of 
such patients results inappropriate management of these patients including unnecessary iron 
therapy. 
 
 1.11. Laboratory diagnosis 
The most important diagnostic criteria to detect Thalassemia carriers are microcytosis 
(MCV<80 fL) or hyphochromic red cells (MCH<27 pg) (Borges et al., 2001). The α-
Thalassemia trait is suspected when red blood cell indices are reduced, with normal iron stores 
and HbA2 levels. The α
0-Thalassemia is usually associated with a reduction in red cell indices 
(MCV, and MCH) and HbA2 levels (2.2–2.8%), while α
+-Thalassemia shows a very slight 
reduction in MCV (74–82 fL) and MCH (24–26 pg) with normal HbA2 values (2.6–3.1 %) 
(Giambona et al., 2009; Chui, 2005). It is important to note that  altered in red blood cell indices  
aren't specific for  α-Thalassemia,  since it is reduced in different type of hemoglobin disorders. 
No simple biochemical test is able to diagnose the α-Thalassemia trait. Some studies reported 
high prevalence of α-Thalassemia among individuals with microcytosis and hypochromia not 
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due to iron deficiency or β-Thalassemia trait (Borges et al., 2001; Bergeron et al., 2005; 
Alcoforado et al., 2012). Measuring the ratio of α- and β-globin chain synthesis is the most 
direct approach (at the protein level) to diagnose α-Thalassemia (Harteveld and Higgs, 2010).  
The co-inheritance of β-Thalassemia with α-Thalassemia modifies the red blood cell indices, 
which may be almost normalized without a marked effect on HbA2 levels. The co-inheritance of 
β-Thalassemia allele with α+-Thalassemia is less evident: HbA2 is unmodified, and red cell 
indices are slightly higher than with the β-Thalassemia allele alone (Chui, 2005; Giambona et 
al., 2009).  
Individuals with a single α-globin gene deletion or non-deletion mutation can have normal 
blood counts (Chui, 2005). A deficiency of α-globin chains leads to production of excess γ-
globins that form γ4 tetramers (Hb Bart's) in the fetus, and the amount of Hb Bart's in the cord 
blood may be used to predict the genotype of α-Thalassemia in the neonates (Fucharoen and 
Winichagoon, 2011). 
 
HbH inclusion bodies are traditionally used for the detection of α+-Thalassemia trait, these can 
be identified by staining the peripheral blood with 1% brilliant cresyl blue (Harteveld and 
Higgs, 2010). This procedure is laborious, and has limited sensitivity. An enzyme-linked 
immunosorbent assay (ELISA) to detect embryonic ζ-globin chains in adult erythrocytes can be 
used as a screening test for carriers of the (-α SEA) α-thalassaemia deletion (Chui, 2005). 
In pregnant women with fetuses affected with Hb Barts syndrome, fetal erythrocytes containing 
only embryonic ζ-globin chains and not the adult α-globin chains can be detected very early in 
pregnancy (Chui, 2005). 
HbA2 Levels are often performed as part of the laboratory investigation to diagnose Thalassemia 
carriers. If the HbA2 level is elevated (>3.5%), the individual is considered to be a carrier for β-
Thalassemia. If the HbA2 level is normal or low, the person is suspected to be a carrier for α-
Thalassemia (Urbiant et al., 2006). A borderline level of HbA2 (3.5% ± 0.4) may also exist when 
β-Thalassemia mutations are co-inherited with other molecular defects (α- and δ-Thalassemia) 
(Giambona et al., 2009)  
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Hemoglobin electrophoresis was shown that hemoglobin Bart’s screening of fresh umbilical 
cord blood is an effective method to evaluate α-globin chain imbalance, this strategy could be 
used to screen populations of high incidence of α-Thalassemia (Rugless et al., 2006). In 
neonates affected with HbH disease, Hb Bart’s constitute about 25% at delivery with a 
decreased level of HbA, HbA2 and HbF. In adults affected with HbH disease, HbH eventually 
replaces Hb Bart’s and makes up from 2% to 40% of the total hemoglobin (Chui et al., 2003). 
Hb Bart’s has been used as a marker for the presence of α-Thalassemia in newborns although 
its detection underscores the incidence rate. Other methods for the detection of α-Thalassemia 
include immunological determinations of Hb Bart’s and ζ chains (Baysal, 2011). DNA 
diagnosis from chorionic villi or amniotic fluid fibroblasts can detect Hb Bart's hydrops fetalis 
as early as 10-16 weeks of gestation (Fucharoen Winichagoon, 2011) 
 
Hemoglobinopathies including Thalassemia were the first genetic diseases to be diagnosed at 
the molecular level which represents the definitive diagnosis for α-Thalassemia. Gap-PCR is 
used to amplify regions across the breakpoints of the deletion of the α-gene. This technique 
provides a quick diagnostic test for α+-Thalassemia and α0-Thalassemia deletional mutations 
(Tan, et al., 2001). This method is applied to detect the 2 most common α+ Thalassemia 
deletions -α3.7and -α4.2 and the five common α0-thalassaemia deletions -α20.5, -- SEA/,  -- MED/, -- 
Thai and - - Fil (Harteveld and Higgs, 2010). 
Point mutations can be detected by different types of PCR such as: Amplification Refractory 
Mutation System (ARMS PCR) and Restriction Fragment Length Polymorphism (RFLP PCR).  
However, DNA sequencing is used to confirm sequence variation or to detect new mutations 
(Clark and Thein, 2004). 
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1.12. Treatment of Thalassemia 
 
α-Thalassemia minor do not require treatment. Treatment for HbH disease depends on the 
severity of the clinical picture which can vary widely. Transfusions are rarely indicated. 
Anemia requires regular substitution with folic acid. For Hb Bart’s syndrome, transfusions are 
required in uterus and continuously after birth. (Chui, 2005;  Kohne, 2011). 
 
Nearly all fetuses with the Hb Barts hydrops fetalis syndrome are stillbirths or die shortly after 
birth (Chui, 2005). Intrauterine transfusion therapy appears promising in minimizing the 
morbidity and mortality of homozygous α-Thalassemia. Recent advances in stem cell 
transplantation have resulted in some patients being cured (Vichinsky, 2009). 
 
1.13. Objectives of the study 
The objectives of this study are: 
1. To determine the prevalence of a five α-globin gene mutations (-α3.7/, –α4.2/ , α2-IVSI-5nt, --
MED / and αααanti3.7) among a cohort of Palestinian patients with microcytosis not due to iron 
deficiency or β-Thalassemia trait. 
2. To determine the approximate incidence rate of α-Thalassemia among a cohort of Palestinian 
patients with microcytosis not due to iron deficiency or β-Thalassemia trait. 
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Chapter Two: Materials and Methods  
 
 
2.1. Materials  
2.1.1. Reagents and chemicals 
All reagents and chemicals used for this study are shown in Table 5. All materials used were of 
molecular biology grade. 
 
                  Table 5:  Materials used in the study. 
Material Source/Manufacturer 
Genomic DNA Extraction kit BIONEER/ K-3032 
HotStart PCR Pre Mix BIONEER/ K-5050 
Gel Purification Kit BIONEER/ K-3034 
Tris base Sigma 
Ethidium bromide (10 mg/ml) HyLabs/ BP451 
DNA molecular weight 
marker 100bp 
GeneDirex 
DNAase free nuclease water Hylab 
Dimethyl sulfoxide (DMSO) Sigma 
EDTA Sigma 
Agrose Hylab 
 
2.1.2. PCR primers 
All PCR primers were obtained from Metabion Company (Germany).  DNA sequences and 
nucleotide position of PCR primers are shown in Table 6. The primers P51 to P72 were used for 
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gap-PCR analysis of deletion mutations in α-globin genes (Oron-Karni et al., 2000). While the 
primers α-CF, α1-R1 and α2-R2 were used for DNA sequencing of α-globin genes (Clark and 
Thein, 2004). The primers IVSID52W, A2D5M and A2R904 were used for ARMS PCR 
analysis of the α2-IVSI -5nt mutation. These primers were described earlier by Lacerna et al. 
(2007) but A2D5M was slightly modified and the primer IVSID52W was redesigned to 
increase the specificity of the RCR. 
Table 6: Sequence and location of PCR primers. 
Primer Sequence (5’→3’) GenBank   
Accession  no. 
Coordinates Gene 
P51 CTGCACAGCTCCTAAGCCAC J00153 7254-7273 
11072-11091 
α2 
α1 
P52 CCTCCATTGTTGGCACATTCC J00153 7531-7551 α2 
P54 CTCAAAGCACTCTAGGGTCCA J00153 11497-1517 α1 
P55 GTCCACCCCTTCCTTCCTCA J00153 5687-5706 
9247-9266 
Y21 
Y11 
P59 CTCTAGGTCACCCTGTCATCA J00184 26-46 Ψζ1 
P60 CTCTGTCGTGTAGACGCCGA M33022 423-442 θ2 
P71 TACCCATGTGGTGCCTCCATG J00153 3068-3088 Ψα1 
P72 TGTCTGCCACCCTCTTCTGAC J00153 8894-8915 NH-II2 
α-CF GGAGGGTGGAGACGTCCTG Z84721 33538-33556 
37344-37360 
α2 
α1 
α1-R1 CGAGAGGTTCTAGCCATGTGTG Z84721 38453-38474 α1 
α2-R2 CCATTGTTGGCACATTCCGG Z84721 34602-34621 α2 
 
IVSID52
W 
GGAGGCCCTGGAGACGTG AG Z84721 33847-33877 α2 
 
A2D5M GTATGGTGCGGAGGCCCT 
GGAGACGC 
Z84721 33856-33875 α2 
 
A2R904 GTCTGAGACAGGTAAACA 
CCTCCAT 
Z84721 34642-34618 α2 
1 Y1 and Y2 refer to homologous regions Y1 and Y2 overlapping α2 and α1-globin genes. 
2 NH-II: non-homologous region 2. 
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Figure 5 shows the physical maps of the human α-globin gene cluster and the location of PCR 
primers (P51 to P72) used for analysis of deletion mutations.    
 
 
Figure 5:  Alpha-globin gene cluster and the location of PCR primers P51 to P72. (A) Physical map 
of α-globin gene cluster and the --Med deletion. Solid boxes represent functional genes and open boxes 
represent pseudogenes. The dashed line designates the --Med deletion. (B, C) The locations of the 
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homologous (X, Y, and Z boxes, denoted as stippled, black, and hatched, respectively) and non-
homologous regions (I, II, and III) in the α-globin cluster are shown, as well as the products of unequal 
crossing over between the Z boxes (--α3.7/ and αααnti3.7) and X boxes (--α4.2/). The locations of the PCR 
primers and the sizes of the expected amplicons are shown under each gene map (Oron-Karni et al., 
1998).  
 
2.2. Methods 
 
2.2.1. Patients 
 
The study population consisted of two groups: patients and neonates. Patients included in the 
study were presenting with microcytosis (MCV<80 fL) not due to iron deficiency anemia or β-
Thalassemia trait. The β-Thalassemia trait was excluded by the finding of normal HbA2 level 
following hemoglobin electrophoresis. For the exclusion of iron deficiency anemia we first 
assumed that for the investigation of microcytosis, iron studies should be performed as first line 
tests and if normal, then testing for β-Thalassemia trait should follows. This assumption is 
based on the clinical protocols adopted by the Primary Health Care clinics in the Ministry of 
Health. However, the clinical protocols for investigation of microcytosis were not implemented 
consistently. Therefore, we have applied the Menzer Index (for exclusion of iron deficiency; 
see section 2.2.3) on all samples with microcytosis and referred for investigation of β-
Thalassemia trait. The exclusion of iron deficiency would have been more accurate if the study 
samples were tested for serum ferritin or serum iron, but such testing was not done in this study 
and it is a limitation of the present study. Patients fulfilling the above mentioned criteria and 
referred to the Specialized Medical Laboratories in Ramallah for investigation of β-Thalassemia 
trait by Hemoglobin electrophoresis were asked to participate in this study. 
 
For the neonatal group, the samples were collected from neonates delivered at the Palestinian 
Red Crescent Society Hospital at Al-Bireh. During the study period, neonates referred to the 
hospital laboratory for CBC analysis and were found to have an MCV<95 fL, the neonates’ 
families were asked to donate their blood samples for this study.  
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2.2.2. Sample collection and processing 
 
EDTA-blood samples were collected from patients referred to the Specialized Medical 
Laboratories in Ramallah for investigation of β-Thalassemia trait by hemoglobin 
electrophoresis from September 2010 to January 2012. Samples with MCV<80 fL and normal 
HbA2 levels (<3.5 %) were included in this study, provided that iron deficiency anemia is 
excluded as described in the previous section (2.2.1). Blood samples from neonates were 
collected during same period from the Palestinian Red Crescent Society Hospital in Al-Bireh. 
Blood samples were stored at 4˚C after Complete blood count (CBC) analysis and DNA 
extraction was performed within 1-2 weeks of blood collection. 
 
The Specialized Medical Laboratories in Ramallah performs hemoglobin electrophoresis using 
HPLC based method (Tosoh Instrument) and is one of the main medical laboratories that 
performs this test in the West Bank. Specialized Medical laboratories receive samples from 
various medical laboratories in the West Bank.  
 
The following figure shows the process from sample collection, sample processing, the PCR 
reactions for deleted mutation, DNA sequencing for representative samples, to ARMS PCR for 
remaining samples. 
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Figure 6:  The flow of sample processing and analysis performed in this study. Gap-PCR was 
performed for detection of the deletion mutations –α3.7/, -α4.2/ and -- MED/, and αααanti3.7 
triplication. ARMS PCR was performed for detection of the α2-IVSI -5nt mutation. DNA 
sequencing covered the whole α1- and α2-genes including the promoter region and the 3’UTR. 
12 negative  
Sample collection 
Patients with 
MCV<80fL
MCH<27 pg  
Neonate MCV < 95fL 
GAP PCR   
Patients with 
HbA2<3.5 (n=200) 
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GAP PCR   
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DNA Seq  n=1 
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2.2.3. Mentzer Index 
 
The Mentzer index is used to differentiate iron deficiency anemia from β-Thalassemia trait 
(Ntaios et al., 2007). The Mentzer index (MCV/red blood cell count) can help distinguish 
between iron deficiency and β-Thalassemia trait. In iron deficiency, the ratio is usually greater 
than 13, whereas β-Thalassemia trait yields values less than 13. A ratio of 13 would be 
considered uncertain (Kohne, 2011). A group of the patients’ samples have Mentzer index 
higher than 13 and have RBC count more five millions per µL. The RBC count is also useful as 
a diagnostic criterion because β-Thalassemia trait produces a microcytic anemia that is usually 
associated with an increase in the RBC count. While microcytic anemia, including iron 
deficiency and anemia of chronic disease, are usually associated with a decrease in the RBC 
count that is proportional to the degree of decrease in Hb concentration (Clarke and Higgins, 
2000). A RBC count less than 5.0x106µL would most likely indicate iron deficiency, but a RBC 
count above 5x106 µL would most likely indicate β-Thalassemia trait (AlFadhli et al., 2006). 
 
2.2.4. DNA Extraction 
 
Genomic DNA was extracted from peripheral whole blood by the AccuPrep Genomic DNA 
Extraction Kit (Bioneer) per the manufacturer’s instructions. This kit yields an average of 6µg 
of genomic DNA from 200 µL of whole blood. AccuPrep genomic DNA Extraction Kit 
employs glass fibers, fixed in a column, which specifically binds DNA in the presence of a 
chaotropic salt. Proteins and other contaminants are eliminated through a series of short wash 
and spin steps. Then the genomic DNA is eluted by a low salt solution (10 mM Tris, pH 8.0).  
 
Briefly, 20 µL of protinase K was added to 200 µL of whole blood, then 200 µL of binding 
buffer was added followed by immediate, short vortexing and incubated at 60°C for 10 minutes. 
After incubation, 100 µL of isopropanol was added, the lysate was transferred to the reservoir 
of the binding column tube and spined at 8000 rpm for 1 minute. The binding column was 
transferred to a new 2 ml tube, washed with 500 µL of washing buffer 1 followed by a second 
wash with 500 µL of washing buffer 2. The DNA was eluted from the binding column using 
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200 µL of elution buffer (10 mM Tris, pH 8.0).  The genomic DNA was stored at -20 °C until 
testing. 
 
2. 2.5. Assessment of DNA quality and quantity  
 
For assessment of DNA quality, 5 µL of DNA sample was mixed with 1 µL 6X DNA gel 
loading dye, loaded on 0.8% agarose gel and electrophoresed at 5-8 volt/cm.  A 1 kb DNA 
ladder was run in each electrophoresis run and samples with positive band only were used for 
the PCR testing. 
 
For quantification of DNA, the DNA concentration was measured spectrophotometrically at 
260 nm. The ratio 260/280 was also calculated and used to further assess the quality of DNA 
samples.  
 
2.2.6. Polymerase Chain Reaction (PCR) 
 
2.2.6.1. Gap-PCR 
 
First trial: Three multiplex Gap-PCRs were performed as described by Liu et al. (2000). This 
method consist of three multiplex PCR reactions: (1) the α0 reaction which detects --α20.5 and --
αMED, (2) the -α4.2 reaction which detects -α4.2/ deletion and (3) the -α3.7 reaction which detects 
the -α3.7/ deletion and αααanti3.7 rearrangement. Each one of these three Multiplex PCRs 
consisted of 2-3 pairs of primers (Table 2.7), and one of these primer pairs is designed to 
amplify a sequence alongside the mutation-specific sequence that served as an internal control 
for each reaction. For this PCR method, several optimization steps were performed and 
included: testing of each primer pair separately and in combination, adjustment of the annealing 
temperature, primer concentration and, addition of PCR enhancers such as DMSO (2-10%), 
Formamide (1-4%) and Betaine (1.5 M) either separately or in combination. Following these 
optimization steps, the α0 reaction gave the internal control amplicon in some samples and 
detected the --αMED/ mutation in some samples. The -α4.2 reaction was not successful and did not 
yield any of the expected amplicons. The -α3.7 reaction gave the expected internal control 
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amplicon in most samples tested and detected the –α3.7/ mutation in some samples. The 
difficulties experienced in the previous reactions can be explained partly by the high GC 
content of the α-globin gene cluster as well as to the poor primer design. Therefore these three 
gap-PCR reactions were replaced by a new set of primers, described in the following paragraph. 
  
Table 7:  Sequence of the PCR primers as described by Liu et al. (2000). 
Primer Sequence (5’ to 3’) Amplicon 
size  
 
α
0 
multiplex PCR: α-SEAF + α-R + 20.5(F+R) + MED (F+R). 
α-SEAF CTCTGTGTTCTCAGTATTGGAGGGAAGGAG 
α-R TGAAGAGCCTGCAGGACCAGGTCAGTGAC
CG 
1010 bp 
(Internal 
control) 
20.5(F) GGGCAAGCTGGTGGTGTTACACAGCAACT
C 
20.5(R) CCACGCCCATGCCTGGCACGTTTGCTGAGG 
875 bp 
MED(F) CGATGAGAACATAGTGAGCAGAATTGCAG
G 
MED(R) ACGCCGACGTTGCTGCCCAGCTTCTTCCAC 
1187 bp 
 
-α 
3.7
multiplex PCR: 3.7(F) + 3.7(R1) + 3.7(R2) 
- α
3.7
:   
3.7(F) AAGTCCACCCCTTCCTTCCTCACC 
3.7(R2) TCCATCCCCTCCTCCCGCCCCTGCCTTTTC 
 
1963 bp 
ααα
anti3.7
:   
3.7(F) AAGTCCACCCCTTCCTTCCTCACC 
3.7(R1) ATGAGAGAAATGTTCTGGCACCTGCACTTG 
2440 bp 
αα:   
3.7(F) + 3.7(R1) (see sequence above) 2217 bp 
3.7(F) + 3.7(R2) (see sequence above) 2213 bp 
 
-α
4.2
 multiplex PCR: 4.2(F) + 4.2(R1) + 4.2(R2) 
-α
4.2
:   
4.2(F) TCCTGATCTTTGAATGAAGTCCGAGTAGGC  
 
4.2(R2) ATCACTGATAAGTCATTTCCTGGGGGTCTG 
1725 bp 
αα:   
4.2(F) TCCTGATCTTTGAATGAAGTCCGAGTAGGC  
 
4.2(R1) TGGGGGTGGGTGTGAGGAGACAGGAAAGA
GAGA 
1510 bp 
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Second trial: In this trial four multiplex Gap-PCRs (A to D reactions were performed), Table 8 
in this table summarizes the expected genotypes, primers and amplicon size as in the original 
article) were performed as described by Oron-Karni et al. (1998) with some modifications. The 
results reported in this study and the discussion all refer to this trial. The sequences of PCR 
primers used in this trial are shown in Table 2.6 (primers P51 to P72). Reaction A is a multiplex 
reaction which detects the –MED/ mutation and contains the following primers: P51 (60 ng), P52 
(40 ng), P54 (60 ng), P59 (40 ng), and P60 (40 ng). Reaction B detects the - α3.7/ mutation and 
contains the following primers: P55 (60 ng) and P54 (60 ng). Reaction C detects the -α4.2/ 
mutations and contains the following primers: P71 (40 ng), P72 (60 ng), and P52 (20 ng). 
Reaction D detects the αααanti3.7 triplication and contains the following primers: P55 (59 ng), 
P52 (63.08 ng).  
 
Table 8:  The α-globin gene genotypes detected using the multiplex gap-PCRs and the size of 
the corresponding amplicons in bp. 
PCR reaction 
 —Med 
A 
-α3.7 
B 
-α4.2 
C 
αααanti3.7 
D 
Primers → 
Alleles ↓ 
P59-P60 P51-P52 P51-P54 P55-P54 P71-P52 P55-P52 P55-P52 
Αα - 298 446 2271  233 1865 
-MED 561 - - -  - - 
-α4.2 -  446 2271 1596 - - 
-α3.7 -  446 2013  233 - 
ααα anti3.7       1865,2123 
 
 
All PCR reactions (reactions A to D) were performed with a HotStart ready PCR mix (Bioneer) 
using ~100 ng of genomic DNA and 5 % DMSO.  Each 20-µL reaction contained the 
manufacturer’s buffer (1X), 1.5 mM MgCl2, 0.25 mM of each dNTP and Hot-Satrt Taq DNA 
Polymerase. Bioneer's Hot-Start Taq DNA polymerase is designed for hot-start PCR to provide 
higher PCR specificity by use of Pyrophosphatase and Pyrophosphate method. 
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Amplification was performed with an initial heat activation step of 5 minutes at 94°C followed 
by 35 cycles, each consisting of 94°C 1 minute, 58°C for 1 minute, and 72°C for 2.5 minutes, 
and a final extension step of 72°C for 10 minutes. Thermal cycling was performed using a 
Biometra DNA thermal cycler (Germany). 
 
2.2.6.2. ARMS PCR 
 
 (ARMS) PCR was used for detection of the α2-globin gene mutation that termed α2-IVSI-5nt 
deletion. This mutation involves deletion of the first 5’ nucleotides in intron 1 (IVSI) in the  α 
2-globin gene. The PCR reaction was performed with a Hot-start ready PCR mix (Bioneer) 
using ~100 ng of genomic DNA and 5 % DMSO.  Each 20-µL reaction contained the 
manufacturer’s buffer (1X), 1.5 mM MgCl2, 0.25 mM of each dNTP, 0.25 µM of each forward 
and reverse primers and Hot-start Taq DNA Polymerase. The mutant sequence was amplified 
using the forward primer A2D5M and the common reverse primer A2R904. The Wild type 
sequence was amplified using the forward primer IVSID52W and the common reverse primer 
A2R904. Bioneer's Hot-start Taq DNA polymerase is designed for hot-start PCR to provide 
higher PCR specificity by use of Pyrophosphatase and Pyrophosphate method. 
 
Amplification was performed with an initial heat activation step of 5 minutes at 94°C followed 
by 30 cycles, each consisting of denaturation at 94°C for 50 seconds, annealing at 60°C for wild 
type reaction or 62°C for the mutant reaction for 50 seconds, and extension at 72°C for 1 
minute and a final extension step of 72°C for 5 minutes. Thermal cycling was performed using 
a Biometra DNA thermal cycler (Germany). 
 
 
2.2.7. Agarose gel electrophoresis 
 
For preparation of agarose gels, appropriate amount of agarose was dissolved in 1X TAE buffer 
by heating, allowed to cool to 50˚C and then ethidium bromide was added to a final 
concentration of 0.5 µg/ml. A 2% gel was prepared for reactions A and D and 1.4 % gel for 
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reactions B and C. The gel solution was poured in an electrophoresis tray with appropriate 
comb and allowed to polymerize at room temperature.  
 
For analysis of PCR amplicons, 10 µL of each PCR reaction product was mixed with 2 µL of 6 
X DNA gels loading dye and electrophoresed at 80 voltage for 45 minutes. A 1 Kb DNA leader 
was run in each run. Then the gels were visualized on a UV transilluminator. 
 
2. 2.8. DNA Sequencing 
 
Nine DNA samples with microcytosis and hypchromia, with normal HbA2 and with no deletion 
mutations in the α–globin genes were subjected for complete DNA sequencing of α1- and α2-
globin genes. The α1- and α2-globin genes were amplified separately using PCR primers 
described by Clark and Thein 2004, (Table 2). The α2-globin gene was amplified using the 
primer pair: α-CF and α2-R2, which yields an amplicon of 1084 bp long. While the α1-globin 
gene was amplified using the primer pair: α-CF and α1-R1, which yields an amplicon of 1131 
bp long.  
 PCR amplification was performed using Hot-start ready PCR mix (Bioneer) using ~100 ng of 
genomic DNA and 7.5 % DMSO. Each 20-µl reaction contained the manufacturer’s buffer (1X), 
Hot-Start Taq DNA polymerase, 1.5 mM MgCl2, 0.25 mM of each dNTP and 0.25 µM of each 
primer. 
Amplifications were performed with an initial heat activation step of 5 minutes at 94°C 
followed by 35 cycles, each consisting of  94°C for 1 minute, 55°C for 1 minute and 72°C for 
1.5 minute, followed by a final  extension step of 72°C for 5 minute. Thermal cycling was 
performed in a Biometra DNA thermal cycler (Germany).  
 
The PCR amplicons were separated using 1 % agarose gel and the target gel band was excised. 
The PCR amplicons were purified from the agarose gel slices using the AccuPrep DNA 
Purification kit (Bioneer) per the manufacturer’s instructions. Briefly, the gel slice was 
dissolved in 3 volumes of Buffer 1 at 60˚C for 10 minutes. The gel mixture was transferred to 
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the binding column, washed twice with Buffer 2 and finally eluted with 30-50 µl of 10 mM Tris 
buffer, pH 8.0.  
 
The purified PCR amplicons were sent to the Heredity Research Laboratory at Bethlehem 
University for DNA Sequencing. The DNA sequencing was performed by the Dideoxy Chain 
Termination method and Big DyeV1.1 Terminator reagents (Applied Biosystems) and 
sequenced on the automated ABI 3130 Genetic Analyzer (Applied Biosystems). Each α-gene 
was sequenced using the forward and reverse primers. 
 
2.2.9. Analysis of DNA sequences 
 
DNA sequences were viewed using the Chromas Lite software 2.01 
(http://www.technelysium.com.au/chromas_lite.html) and the DNA sequences were analyzed 
using the BLAST program (http://blast.ncbi.nlm.nih.gov/) against the DNA sequence of α-
globin gene cluster available under the GenBank accession no. Z84721.1. 
 
2.2.10. Statistical analysis  
 
The mean and standard deviation for total Hb, RBC count, MCH, MCV and RDW were 
calculated using Excel program/ Microsoft office 2007. To compare the hematological 
parameters mentioned before, a one-way ANOVA was used (SigmaStat 2.03). Comparisons 
between groups were made with Tukey test. Statistical significance was assessed as a test with 
p <0.05. 
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Chapter Three: Results 
 
 
3.1 Study Samples 
 
This study was carried out to investigate the prevalence of α-globin gene mutations among 
Palestinian patients with microcytosis not due to iron deficiency or β-Thalassemia trait. For this 
purpose, a convenient sample of 200 nonrelated patients was collected in the period September 
2010 to January 2012 at the Specialized Medical laboratory in Ramallah. All patients included 
were presenting with microcystosis, referred for investigation of β-Thalassemia trait by Hb 
electrophoresis and were found to have HbA2 level below 3.5%. The exclusion of iron 
deficiency was based on application of the Menzer Index <13, or RBC count >5.0 x106/µL). 
Seventy -three samples were found to have a Menzer Index <13 or RBC count >5.0x106/µL and 
thus unlikely to have iron deficiency. These 73 samples (146 nonrelated chromosomes) were 
further subjected for investigation of α-globin gene mutations. There was a preponderance of 
male patients (M/F=45/28). 
A second group of 19 nonrelated neonates (38 chromosomes) for whom blood samples were 
referred to the laboratory for CBC analysis and were found to have an MCV<95 fL at the 
Palestinian Red Crescent Society Hospital at Al-Bireh during the study period. It has been 
confirmed that an MCV below 90fL and MCH below 30pg is a strong indicator of the presence 
of α-Thalassemia minor (Tritipsombut et al., 2008; Akram, et al., 2009). 
 
3.2 Hematological parameters for all study samples 
The red cell indices, Hb values and HbA2 level for all samples (73 patients and 19 neonates) 
that fulfilled the study criteria are shown in Appendix A. All patients’ samples showed 
microcytosis and hypochromia, normal hemoglobin A2 level and Menzer Index <13, or RBC 
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count >5x106 / µL (Appendix A). The neonatal samples also showed microcytosis with MCV 
<95 fL (Appendix A). 
3.3 α-Thalassemia mutations 
Identification of the α-Thalassemia mutations among the study samples was performed using 
gap-PCR, DNA sequencing of representative samples and ARMS PCR. Four different 
multiplex gap-PCR reactions (Reactions A to D) were performed for detection of four deletion 
mutations affecting the α-globin genes: -α3.7/, -α4.2/, --MED/ and αααanti3.7. These mutations 
represent the most prevalent deletion mutations affecting the α-globin genes in the 
Mediterranean region. Representative agarose gels for each mutation are shown in Figures 7 to 
10.  
 
 
 
 
 
 
Figure 7: Representative agarose gel for the –MED/ multiplex PCR reaction.  Lanes 1-3 & 5-7: 
negative for --MED/αα mutation, Lane 4: --MED/αα genotype, Lad: 100 bp DNA ladder.  
 
 
 
561    
446  
293  
     2       3          4        led        5           6       7           1  
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Figure 8:  Representative agarose gel for the –α3.7 PCR reaction.  Lanes 1, 4 & 6: negative for-
α3.7/-α3.7 mutation, Lane 2 & 3: -α3.7/-α3.7 genotype, Lanes 5: -α3.7/αα genotype, Lad: 1 kb DNA 
ladder.   
 
 
 
Figure 9: Representative agarose gel for the –α4.2 PCR reaction.  Lanes 1-7: negative for –α4.2   
mutation, Lad: 100 bp DNA ladder.   
 
Figure 10: Representative agarose gel for the αααanti3.7 PCR reaction.  Lane 1: αααanti3.7 
triplication, Lanes 2-4: negative for αααanti3.7 triplication, Lad: 1 kb DNA ladder.   
 
  38
 
From the samples that were negative for the deletion mutations tested by gap-PCR, eight 
samples from the patients’ group and one sample from the neonate group were selected 
randomly and subjected for DNA sequencing of α2- and α1-globin genes. DNA sequencing has 
revealed that four patients’ samples and 1 neonate sample were heterozygous for the α2-IVSI-
5nt mutation (Figure 11). No other significant genetic variations were observed in DNA 
sequencing.  
 
 
Figure 11:  Identification of α2-IVSI-5nt  mutation by DNA sequencing. (A) Mutant allele; (B) wild 
type allele. The double headed arrow indicates the 5 nucleotides deleted in this mutation. 
 
 
Since the DNA sequencing revealed that more than half of the samples sequenced have the α2-
IVSI-5nt mutation, we have screened all study samples for the α2-IVSI-5nt mutation using 
ARMS PCR (Figure 12). 
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Figure 12: Representative agarose gel for analysis of “α2-IVSI -5nt” mutation by ARMS PCR 
reaction. The amplicon size is 796 bp in the wild type reaction and 790 bp in the mutant 
reaction. L: 50 bp DNA ladder; lanes 1 & 1’: αα/αα genotype; lanes 2 & 2’: α-5ntα/αα genotype; 
lanes 3 & 3’: α-5ntα/α-5ntα genotype; lanes 4 & 4’: positive controls; lanes 5 & 5’: negative 
controls; lanes 6 & 6’: blanks. 
 
Table 9 summarizes the genotypes of α-globin genes detected in this study. From the 73 
patients' samples analyzed, 37 samples (50.7%) were found to have α-glonin gene mutations. 
Twenty-seven patients were heterozygous for one of the four mutation found (-α3.7/; αααanti3.7; --
MED/ and α2-IVSI -5nt ), eight patients were homozygous for either the -α3.7/ or α2-IVSI -5nt  
and two patients were compound heterozygous for the -α3.7/ and α2-IVSI -5nt  mutations.  The 
–α4.2/ deletion mutation was not detected in the study samples. The most prevalent mutation 
was the -α3.7/ deletion mutation and the second most prevalent one was the α2-IVSI -5nt 
mutation. As shown in Table 3.10, 48.9 % of the α-Thalassemia mutant chromosomes detected 
among the patients’ group carried the -α3.7/ deletion mutation and 44.7 % carried the α2-IVSI -
5nt mutation. 
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Table 9: Genotypes of α-globin genes detected among Palestinian patients and neonates. 
Patients Neonates Genotype  
N % n % 
(a) Presumably normal 
genotype 
36 49.3 9 47.4 
(b) Mutant genotype 
-α3.7/αα 
-α3.7/-α3.7 
α-5ntα/αα* 
α-5ntα/α-5ntα 
-α3.7/α-5ntα 
--MED/αα 
αααanti3.7 
37  
11 
5 
13 
3 
2 
2 
1 
50.7 
29.7 
13.5 
35.2 
8.1 
5.4 
5.4 
2.7 
10 
5 
0 
4 
0 
0 
1 
0 
52.6 
26.3 
0 
21.1 
0 
0 
5.2 
0 
Total  73  100 19 100 
*The α-5nt refers to the α2-IVSI-5nt mutation. 
 
Table 10: Frequency of α-Thalassemia mutant chromosomes detected among 
Palestinian patients and neonates. 
Patients Neonates 
Mutation 
n % n % 
 
-α3.7/αα 
α2-IVSI-5nt  
--MED/αα 
αααanti3.7 
 
23 
21 
2 
1 
 
48.9 
44.7 
4.3 
2.1 
 
5 
4 
1 
0 
 
50 
40 
10 
0 
Total 47 100 10 100 
 
For the neonates’ group, 10 samples (52.6%) were found to have α-glonin gene mutations and 
all these 10 samples were heterozygous for one of the three mutation found (-α3.7/, --MED/ and 
α2-IVSI -5nt ) (Table 9). The –α4.2/ deletion mutation was not detected in the neonates group. 
Among the neonates’ group, half (5 out of 10 chromosomes) of the α-Thalassemia mutant 
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chromosomes detected carried the -α3.7/ deletion mutation and 40% of the mutant chromosomes 
(4 chromosomes) carried the α2-IVSI -5nt mutation (Table 10).  
 
3.4 α-Globin genotypes and red cell parameters 
 
Tables 3.11, 3.12 and 3.13 present the various mean values and SD of the red cell parameters 
assessed for each genotype group. In the patients’ group, the proportions of men in the three 
groups were as follows: 61% in group 1, 58% in group 2, 67% in group 3. In Table 3.11, the 
hematological findings of patients’ samples are shown for the whole group as well as for males 
and females separately because the reference range for these parameters is gender dependent.  
 
Table 11: Red cell parameters in the different groups of α-globin genotype detected among the 
patients’ group. 
Patient 
Genotype Sex N % 
RBC 
X10
6
 / 
µL 
Hb g/dL MCV fL 
MCH 
pg/cell 
RDW % HbA2 % 
Group 1: 
Negative for 
the examined 
mutations 
 
All  
Male 
Female 
 
36 
22 
14 
 
49.3 
30.1 
19.2 
 
5.5 ±0.5 
5.6 ± 0.6 
5.2 ± 0.4 
 
11.5 ± 3.1 
12.4 ± 3.3 
10.0 ± 2.1 
 
 
64.5 ± 8.4 
66.0± 8.6 
62.2 ± 7.7 
 
 
20.4±3.6* 
21.3 ± 3.7 
19.0 ± 3.1 
 
 
17.9± 3.3* 
17.0 ± 3.3 
19.2± 2.7 
 
 
2.5 ± 0.4 
2.6 ± 0.4 
2.4 ± 0.5 
 
Group 2:  
Single gene 
defect 
(-α3.7/αα;  
α-5ntα/αα) 
 
All  
Males 
Female 
 
24 
14 
10 
 
32.9 
19.2 
13.7 
 
5.5±0.6 
5.7±0.6 
5.3±0.4 
 
12.2±2.3 
12.7±2.6 
11.7±1.8 
 
68.0±6.0 
68.9±6.2 
67.2±5.7 
 
22.4±2.1 
23.0±2.2 
21.9±1.8 
 
15.9±2.0 
15.6±2.4 
15.9±1.6 
 
2.7±0.5 
2.7±0.4 
2.8±0.5 
Group 3: 
 double gene 
defect  
(-α3.7/-α3.7; α-
5ntα/α-5ntα; 
 -α3.7/α-5ntα; 
- -MED/αα) 
 
All  
Males 
Female 
 
12 
8 
4 
 
16.4 
11.0 
5.4 
 
5.7±0.5 
5.8±0.6 
5.3±0.4 
 
11.7±2.1 
12.3±2.3 
11.7±1.8 
 
62.4±7.1 
64.1±8.0 
67.2±5.7 
 
20.3±2.5 
21.0±2.8 
21.9±1.8 
 
16.8±2.9 
16.8±2.7 
15.9±1.6 
 
2.7±0.4 
2.8±0.4 
2.4±0.3 
 Data are presented as mean ± SD. * The MCH and RDW values marked with an asterisk in 
group 1 are statistically different from respective values in group 2 
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Table 12: Red cell parameters in the different  α-globin genotype detected among the patients’ 
group.   
Patient Genotype Sex  
N % 
RBC 
X10
6
 / 
µL 
Hb g/dL MCV fL MCH 
pg/cell 
RDW % HbA2 
% 
-α3.7/αα 
 
All  
Males 
Females 
 
11 
6 
5 
15.1 
8.2 
6.8 
5.6±0.6 
5.9±0.4 
5.3±0.5 
12.4±2.6 
13.3±2.7 
11.3±2.3 
68.9±6.3 
72.4±4.1 
64.8±6.2 
22.5±2.3 
23.8±1.7 
21.1±2.1 
15.9±1.8 
15.4±1.8 
16.6±1.8 
2.7±0.4 
2.8±0.2 
2.7±0.5 
α-5ntα/αα All  
Males 
Females 
 
13 
8 
5 
17.8 
11.0 
6.8 
5.4±0.6 
5.4±0.7 
5.4±0.3 
12.3±2.2 
12.3±2.7 
12.2±1.3 
67.6±5.8 
66.2±6.4 
69.7±4.4 
22.5±2.0 
22.4±2.5 
22.7±1.1 
15.6±2.3 
15.8±2.9 
15.3±1.2 
2.7±0.5 
2.0±0.5 
2.9±0.5 
-α3.7/-α3.7 
 
All  
Males 
 
 
5 
 
 
6.8 
 
5.7±0.6 
 
12.7±2.8 
 
66.4±8.2 
 
22.1±3.0 
 
16±2.8 
 
2.9±0.5 
α-5ntα/α-5ntα All  
Males 
Females 
3 
2 
1 
4.1 
2.7 
1.4 
5.8±0.3 
6.0±0.3 
5.51 
10.7±0.5 
11.0±0.0 
10.2 
56.4±4.5 
56.7±6.4 
55.9 
18.5±0.7 
18.5±0.9 
18.6 
17.7±2.9 
19.0±2.6 
15.0 
2.5±0.2 
2.6±0.0 
2.3 
-α3.7/α-5ntα All  
Females 
 
 
2 
 
2.7 
 
5.5±0.56 
 
10.3±1.6 
 
61.9±1.7 
 
18.8±0.9 
 
19.0±4.5 
 
2.6±0.5 
--MED/αα All  
Males 
Females 
2 
1 
1 
2.7 
1.4 
1.4 
6.09±0.4 
6.38 
5.8 
12.0±1.6 
13.3 
11.0 
61.8±7.3 
66.9 
56.6 
19.9±1.3 
20.8 
18.9 
15.5±1.6 
16.6 
14.4 
2.5±0.4 
2.8 
2.2 
αααanti3.7 All  
Males 
1 1.4 5.68 11.1 61.6 19.5 18.8 2.8 
Data are presented as mean ± SD. The single sample with α-globin gene triplication (αααanti3.7) 
is included in this table 
 
Table 13: The Various Mean Values of the Erythrocytic Parameters (± SD) For Eeach 
Genotype of Neonate Samples. 
Patients Genotype 
Normal range 
No. % 
RBC 10
6
/ µL 
4.20-6.30 
Hb g/dL 
12.0-18.0 
MCV fL 
80.0-97.0 
MCH pg 
26.0-32.0 
RDW% 
11.5-14.5 
αα/-α3.7 5 26.3 5.17±1.08 15.8±3.5 90.5±2.3 30±4.3 18.2±6.3 
α/--MED 1 5.2 4.32 14.2 93.3 32.9 16.5 
α-5ntα/αα 4 21.0 5.0±0.5 15.6±1 88.5±3.1 31.0±1.9 15.5±1.0 
αα/ αα 9 47.4 4.7±0.7 15.3±2.7 93.4±1.1 31.9±1.8 17.7±4.2 
Total 19 100      
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Statistical analysis between groups for eythrocytic parameters revealed two significant 
differences. The MCH is statistically lower for patients in group1 or those patients who were 
negative for all mutation investigated in this study, than those with a single gene defect (group 
2). In all groups, the mean MCH is less than or equal 27 pg. Patients from group 1 have a 
significantly higher mean RDW compared to patients in group 2. Menzer index is significantly 
lower in group 3 (10.9±1.4) than group 2 (12.5±0.8). The MCH values in patients with double 
gene defect (group 3) were slightly lower than group 2, but statistically not significantly 
probably due to the small number of patients in group 3. The RDW is statistically higher for 
patients in (group1) than those with a single gene defect (group 2). Interestingly, Hb, MCV, 
MCH and RDW showed a similar trend among the three groups, where their values were 
highest in group 2 and values in group 1 and 3 were close together. Although the MCH and 
RDW values were statistically different when comparing groups 1 and 2, there was no distinct 
value that can clearly differentiate between these two groups. 
 
The RBC count in group 2 was slightly higher than in group 1 and in turn RBC count in group 3 
was slightly higher than in group 2. Single and double gene defects in the α-globin genes are 
associated with increased erythrocytosis. The HbA2 level in group 2 was slightly higher than in 
group 1. The mean HbA2 level in group 2 and 3 was very close to each other. 
 
Analysis of the mean values of hematological parameters shown in Table 11 between males and 
females showed that females have lower values in most of these parameters, but these 
differences were statistically not significant. 
 
Analysis of the hematological parameters among the different α-globin genotypes detected in 
this study Table 12 reveals slight differences in mean values but these differences were 
statistically not significant. Also, no significant differences between males and females were 
observed when comparing hematological parameters among the different genotypes detected in 
this study. Samples homozygous for the α2-IVSI-5nt mutation (3 samples) showed a lower 
mean values for Hb, MCV, MCH and HbA2 and higher RDW values compared to samples with 
double gene defect (-α3.7/-α3.7) or samples with single gene defect. The hematological 
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parameters observed in samples with compound heterozygous (-α3.7/α-5ntα, 2 samples) were 
slightly different from other genotypes, but the low sample number of this group does not allow 
a reliable statistical analysis of these differences.  
 
Table 13 compares the hematological parameters among the different genotypes detected in this 
study. Although slight differences exist among the different genotypes, these differences were 
not significant, except MCV and RDW in group 1 and Group 2, Menzer index in group 3 and 
group 2.  
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Chapter four: Discussion  
 
 
 
α -Thalassemia is a group of genetic disorders that result in an imbalance in the synthesis of α  
and β-globin proteins and is caused by different mutations or deletions (Bergeron et al., 2005). 
α-Thalassemia is characterized by a microcytic hypochromic anemia, with variable clinical 
picture ranging from asymptomatic to a fatal hemolytic anemia (Harteveled and Higgs , 2010). 
α-Thalassaemia is more frequently caused by deletion rather than single point mutations or 
nucleotide insertions and deletions involving the sequences controlling gene expression 
(Harteveld and Higgs, 2010). Deletion mutations may involve one or both α-genes on 
chromosome 16. HbH results from deletion of three α-genes. Hydrops Foetalis Syndrome or Hb 
Bart’s disease results from deletion of four α-genes and it is incompatible with life. So far, 
more than 35 deletion mutations affecting the α-genes have been reported. Additionally, the 
number of non-deletional α-globin gene mutations is increasing, and new mutations are still 
being discovered (Chui, 2005).  
 
The aim of this study was to determine the most prevalent α-globin gene mutations based on 
targeted mutation among Palestinian patients with microcytosis not due to IDA or β-
Thalassemia trait. Additionally, the study aimed to determine the most frequent incidence rate 
of α-Thalassemia trait among the analyzed patients with microcytosis not due to IDA or β-
Thalassemia trait. 
 
A total of 200 patients were studied and all patients had hypochromic microcytic (MCV < 80 
fL, MCH <27 pg) anemia. All samples included in the study have a normal Hb electrophoresis 
profile (HbA2 < 3.5%) and Menzer Index <13 and/or RBC count >5x106/µL. Menzer index and 
RBC count are good discrimination function and are used to differentiate IDA from β-
Thalassemia trait (Demir et al., 2002; AlFadhli, et al., 2006; Ehsani et al., 2009). Samples with 
Menzer index <13 or RBC count >5x106/µl are unlikely to have IDA. 
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Nineteen neonate samples were included in this study, all have MCV <95 fL. It has been 
reported that MCV below 90 fL, especially with an MCH below 30pg is a strong indicator of 
the presence of α-Thalassemia minor in neonates (Tritipsombut et al., 2008; Aktam, et al., 
2009). 
For detection of α-Thalassemia mutations among the study population, Gap-PCR, ARMS PCR 
and DNA sequencing were used. Identification of the α-Thalassemia deletion mutations among 
the study samples was performed using multiplex Gap-PCR. Multiplex Gap-PCR uses primer 
pairs that are designed to amplify the region flanking a known deletion generating a unique 
amplicon that will be smaller in the mutant sequence compared with the wild type (Clark and 
Thein, 2004). 
 
Four different multiplex Gap-PCR reactions were performed for detection of four deletion 
mutations affecting the α-globin genes: -α3.7/, -α4.2/. –MED/ and αααanti3.7. These mutations 
represent the most prevalent deletion mutations affecting the α-globin genes in the 
Mediterranean region (Clark and Thein, 2004). Twenty samples were found having deletion 
mutations, and one sample with α-globin gene triplication. But in the neonate samples six 
samples were found having deletion mutations. 
 
To search for point mutations and small insertion/deletion mutations causing α-Thalassemia 
that could orient the search for additional mutations, the α2- and α1-globin genes were 
completely sequenced in eight patients’ samples and one neonate sample. DNA sequencing has 
revealed that four patients’ samples and one neonate sample were heterozygous for the α2-
IVSI-5nt mutation. This mutation results from deletion of five nucleotides at the splice junction 
between exon 1 and intron 1 of the α2-globin gene (Baysal, 2011). No other significant DNA 
sequence variants were observed in DNA sequencing results. However, since DNA sequencing 
was not performed for all study samples, other mutations (other than the mutations investigated 
in this study) cannot be excluded. The α2-IVSI-5nt mutation was found to be the second most 
common mutation after the -α3.7/ deletion mutation among Arabs/Palestinians referred to an 
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Israeli Hospital in Jerusalem (Oron-Karni et al., 2000). In the previous report, the α2-IVSI-5nt 
mutation was reported in 29 chromosomes and the -α3.7/ deletion mutation in 30 chromosomes 
out of the 109 chromosomes studied (Oron-Karni et al., 2000).  
 
Based on the findings of DNA sequencing, which revealed that α2-IVSI-5nt mutation is 
common in our samples, we have analyzed the study samples for this mutation using ARMS 
PCR.   
 
From 73 samples that fulfilled the inclusion criteria for this study, 37 samples (50.7%) were 
found to have α-glonin gene mutations. Twenty-seven patients were heterozygous for one of the 
four mutations found (-α3.7/; αααanti3.7; --MED/ and α2-IVSI-5nt mutations), eight patients were 
homozygous for either the -α3.7/ or α2-IVSI-5nt mutation and two patients were compound 
heterozygous for the -α3.7/ and α2-IVSI-5nt mutations and one sample has a triplication 
mutation, αααanti3.7. The most frequent mutation among the patients’ samples in this study was 
the -α3.7/, where 48.9 % of the mutant chromosomes carried this mutation. The second most 
frequent mutation was the α2-IVSI-5nt and it was found in 44.7 % of mutant chromosomes. 
The other two mutations detected in this study, --MED/ and αααanti3.7, were found in 4.3% and 
2.1% of mutant chromosomes. 
 
From the neonate samples (n=19), ten samples have α-glonin gene mutation, five samples were 
heterozygous for the -α3.7 mutation, four samples were heterozygous for α2-IVSI-5nt mutation 
and one sample was heterozygous for the --MED/ mutation.  
 
The predominance of the α3.7/ deletion is consistent with the findings of several studies in 
different populations and regions.  The α3.7/ deletion is the most common α-globin gene deletion 
mutation among Jews and Palestinians/Arabs in Palestine 1948. This mutation was found in 
63.9% and 27.5 % of mutant chromosomes studied in Jewish and Palestinian/Arab patients 
(Oron-Karni et al. 2000). For the α2-IVSI-5nt mutation, Oron-Karni et al., (2000) reported that 
this mutation is found in only about 3% and 26.6% of mutant chromosomes studied in Jewish 
and Palestinian/Arab patients. Therefore, α3.7/ and α2-IVSI-5nt mutations constitute the most 
frequent mutations among Palestinian/Arab patients in Palestine 1948 (Oron-Karni et al., 2000). 
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The α3.7/ mutation was also reported as the most predominant mutation causing α-Thalassemia 
in several studies from other Arab countries: Kuwait (Diejomaoh et al., 2000), Tunisia, (Zarai et 
al., 2002), Iraq (Al-Allawi et al., 2009), Saudi Arabia (Hellani et al., 2009), Oman (Hassan et 
al., 2010), and United Arab Emirates, (Baysal et al., 2011). Mediterranean countries: Italy 
(Bella et al., 2006), Iran (Zandian et al., 2008; Hossein et al., 2012), and Turkey (Guvence et 
al., 2010). Worldwide: Australia (Prior et al., 2004), North America (Bergeron et al., 2005), 
India (Sankar et al., 2006), China (Xiong et al., 2010), Brazil (Alcoforado et al., 2012), and 
Afro-Amazonian community (Cardoso et al., 2012). Also, an earlier study from eastern Saudi 
Arabia revealed that 45% of α-Thalassemia patients are heterozygotes for this mutation (Al-
Awamy, 2000). In the United Arab Emirates, it was reported that 45% of neonates are carriers 
for this mutation (El-Kalla and Baysal, 1998). 
 
In the neonates’ samples (n=19), ten samples were heterozygous for one of three α-Thalassemia 
mutations, α3.7/,--MED/ and α2-IVSI-5nt. The α3.7/ and α2-IVSI-5nt mutations were the most 
frequent mutations and constituted 50% and 40% of the mutant chromosomes analyzed, 
respectively. The findings of the neonates’ samples are consistent with the finding of the 
patients’ samples. Baysal (2011) reported that the α3.7/ mutation is the most common mutation 
among neonates in United Arab Emirates. 
  
The –MED/ mutation and αααanti3.7 triplication were found in 4.3% and 2.1 % of mutant 
chromosomes in the patients’ samples, respectively. The –MED/ is the third frequent mutation 
among our study sample. Oron-Karni et al. (2000) reported that –MED/ mutation and αααanti3.7 
triplication were found in 4.6 % and 5.5 %, respectively among the Palestinian/Arab 
population, which confirms our findings. However, in other studies the –MED/  mutation was the 
second most frequent α-Thalassemia mutation after the α3.7/ mutation,  as in Jewish (Oron-
Karni et al., 2000) and Kurdish  patients (Al-Allawi et al., 2009). In United Arab Emirates 
(Baysal, 2011) and Iran (Zandian et al., 2008) the –MED/ mutation was found at low frequency, 
where the α2-PolyA (AATAAA>AATAAG or AATGAA) point mutation was the second 
frequent α-Thalassemia mutation after the α3.7/ mutation.   
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The α4.2/ mutation was not detected among our study samples and this is also consistent with 
the findings of Oron-Karni et al., (2000) where this mutation was observed in less than 1% of 
mutant chromosomes among Palestinian/Arab patients. This mutation is also common among 
α-Thalassemia patients in South East Asia and Pacific Islands (Clark and Thein, 2004) and in 
North America (Bergeron et al., 2005). Furthermore, this mutation was reported in about 5 % of 
α-Thalassemia patients in southern Iran (Zandian et al., 2008) and in about 4% in Kurdish 
patients in Dohuk region of Iraq (Al-Allawi, et al., 2009). 
 
In comparison to other reports, it is interesting to note that our finding that the α2-IVSI-5nt 
mutation exists in a high frequency among our study sample and in a frequency close to the α3.7 
mutation. This is novel to the Palestinian population, since till now; similar results have only 
been reported by Oron-Karni et al. (2000) in Palestinian/Arab patients and have not been 
reported in other populations. 
 
Statistical analysis of erythrocyte parameters revealed two significant differences concerning 
the MCH and RDW parameters. The MCH of presumably in (group 1) is statistically lower than 
that in patients with a single gene deletion (group 2) (Table 3.11). Additionally, the Hb values 
and MCV in presumably in (group 1) were slightly lower than those in patients with single gene 
deletion (group 2) (Table 3.11). The sex distribution could not explain for the lower Hb values 
in group 1 compared to group 2, since the proportion of male patients in both groups is very 
close, 61.1 % and 58.3 % respectively. However, these differences are probably explained by 
the fact that group 1 are not a normal control group. In fact group 1 is composed of patients 
with unexplained microcytosis and probably having anemia of mixed etiology or could have 
mutations that are not investigated in the present study. Similarly, the higher RDW in group 1 
compared to group 2 is explained in this manner. When the patient groups with single and 
double gene defects are compared, it was observed that the Hb values, MCV and MCH were 
slightly lower in the group with double gene defect (Table 3.11). While the RBC and RDW 
values were slightly higher in the group with double gene defect compared to single gene 
defect.  Furthermore, there is an overlap between the red cell parameters of the three groups 
analyzed, presumably normal, single and double gene defect (Table 3.11).  Further analysis of 
red cell parameters based on the type of mutation, revealed slight differences among different 
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groups in some cases, but none of these differences were statistically significant (Table 3.12). 
Our findings are consistent with previous reports that also showed that no red cell parameter 
could reliably predict the presence of α-Thalassemia genotype (Bergeron et al., 2005; Mehdi & 
Dahmash, 2011). Molecular diagnosis remains the only reliable method for diagnosis of α-
Thalassemia.  
 
Analysis of the red cell parameters in the neonate group further confirms the value of MCH and 
MCV in the prediction of α-Thalassemia. 
In conclusion, All samples included in the study (the patients' samples and neonate' samples) 
were having unexplained microcytosis. Almost half of the patient's samples and the neonate's 
samples were found to carry one or two of the five α-Thalassemia mutations investigated in this 
study. The α3.7 and α2-IVSI-5nt mutations are the most frequent α-Thalassemia mutations 
among the study samples. 
None of the red cell indices could reliably predict the presence of α-Thalassemia. DNA analysis 
of samples with unexplained microcytosis can reliably detect the presence of α-Thalassemia, 
especially when a wider range of mutations are analyzed, or when samples are analyzed by 
DNA sequencing. 
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Recommendations 
α-Thalassemia should be considered in Palestinian patients with unexplained microcytosis. This 
observation was confirmed by the finding that about half of the study samples have one or two 
of the five α-Thalassemia mutations investigated in the present study (-α3.7; -α4.2, αααanti3.7; --MED 
and α2-IVSI-5nt mutations). DNA analysis can reliably detect the presence of α-Thalassemia 
mutations. Testing for the α3.7 and α2IVSI 5nt mutations should be considered as the first step in 
DNA analysis of α-Thalassemia, as these two mutations were found in 48.9 % and 44.7 %, 
respectively, of mutant chromosomes identified in this study. 
Further studies are needed to study the prevalence and genotypes of α-Thalassemia in a larger 
cohort of Palestinian patients with unexplained microcytosis. Genotyping of α-Thalassemia 
mutations should be preferably performed using Gap-PCR for detection of large deletion 
mutations and DNA sequencing for detection of other types of mutations. 
  52
 References 
 
Akram, A., Khalida, A., Sawsan, S., and Charles, L. (2009). Birth MCV and MCH are quite 
reliable parameters for the prediction of alpha Thalassemia trait. Clin. Med.: Blood Disorders. 
2, 1-4. 
Al-Allawi, N.A.S., Badi, A.I.A., Imanian, H., Nikzat, N., Jubrael, J.M.S., and Najmabadi, H. 
(2009). Molecular characterization of α-Thalassemia in the Dohuk region of Iraq. Hemoglobin. 
33(1), 37-44. 
Al-Awamy, B.H. (2000). Thalassemia syndromes in Saudi Arabia. meta-analysis of local 
studies. Saudi. Med. J. 21(1), 8-17. 
Alcoforado, G.H.M., Bezerra, C.M., Lemos, T.M.A.M., De Oliveira, D.M., Kimura, E.M., 
Costa, F.F., Sonati, M.F., and Medeiros, T.M.D. (2012). Prevalence of α-Thalassemia 3.7 kb 
deletion in the adult population of Rio Grande do Norte, Brazil. Genet. Mol. Biol. 35, 594-598. 
AlFadhli, S.M., Al-Awadhi, A.M., and AlKhaldi, D. (2007). Validity assessment of nine 
discriminant functions used for the differentiation between iron deficiency anemia and 
Thalassemia minor. J. Trop. Pediatr .53, 93-97.  
 
Bank, A., and Ramirez, F. (1978). The molecular biology of Thalassemia. Crit. Rev. Biochem. 
343-368. 
Baysal, E. (2011). Alpha-Thalassemia syndromes in the United Arab Emirates. Hemoglobin. 
35(5-6), 574-580. 
 Bella, C.,  Salpietro, C., La Rosa, M., Cuppari, C., Piraino, B., Cutri, M.R., and Rigoli, L. 
(2006). Identification of α-Thalassemia mutations in subjects from Eastern Sicily (Italy) with 
abnormal hematological indices and normal Hb A2. Ann. Hematol. 85(12), 829–831. 
Bergeron, J., Weng, X., Robin, L., Olney, H.J., and Soulieres, D. (2005). Prevalence of α globin 
gene deletions among patients with unexplained microcytosis in a North American population. 
Hemoglobin. 29(1), 51-60. 
  53
Borges, E., Wenning, M.R., Kimura, E.M., Gervasio, S.A., Costa, F.F., and Sonati, M.F. 
(2001). High prevalence of alpha-Thalassemia among individuals with microcytosis and 
hypochromia without anemia. Braz. J.  Med. Biol. Res. 34(6), 759-762.  
Cardoso, G.L., Takanashi, S.Y., and Guerreiro, J.F. (2012). Inherited hemoglobin disorders in 
an Afro-Amazonian community: Saracura. Genet. Mol. Biol. 35(3), 553-556. 
Chong, S.S., Boehm, C.D., Higgs, D.R. and Cutting, G.R. (2000). Single-tube multiplex-PCR 
screen for common deletional determinants of alpha-Thalassemia. Blood. 95(1), 360-362. 
Chui, D.H. (2005). Alpha-thalassaemia and population health in Southeast Asia. Ann. of Hum. 
Biol. 32(2), 123–130. 
Chui, D.H., and Waye, J.S. (1998). Hydrops Fetalis caused by alpha Thalassemia: an emerging 
health care problem. Blood. 91(7), 2213-2222. 
Chui, D.H., Fishermen, S., and Chan, V. (2003). Hemoglobin H disease not necessarily a 
benign disorder. Blood. 101(3), 791-796. 
Clark, E., and Thein, L. (2004). Molecular diagnosis of hematological disorders. Clin. Lab. 
Haematol. 26, 159-176. 
Clarke, G.M., and Higgins, T.N. (2000). Laboratory investigation of hemoglobinopathies: 
review and update. Clin. Chem., 46 (8 Pt 2), 1284-90. 
Darwish, H., El-Khatib, F., and Ayesh, S. (2005). Spectrum of β- globin gene mutation among 
Thalassemia patients in the West Bank region of Palestine. Hemoglobin. 29, 119–132. 
Demir, A., Yarali, N., Fisgin, T., Duru, F., and Kara, A. (2002). Most reliable indices in 
differentiation between Thalassemia trait and iron deficiency anemia. Pediatr Int. 44(6), 612-
616. 
Diejomaoh, F.M.E., Haider, M.Z., Dalal, H., Abdulaziz, A., D'Souza, T.M., and Adekile, A.D. 
(2000). Influence of alpha-Thalassemia trait on the prevalence and severity of anemia in 
pregnancy among women in Kuwait. Acta. Haematol. 104(2-3), 92-94.  
  54
Ehsani, M.A., Shahgoli, E., Rahiminejad, M.S., Seighali, F., and Rashidi, A. (2009). A new 
index for discrimination between Iron Deficiency Anemia and Beta-Thalassemia minor: Results 
in 284 patients. Pak. J. Biol. Sci. 12(5), 473-475. 
Elgawhary, S., Elbaradie, M.Y., Rashad, M.W., Mossad, M., Abdella, M.A., Ezzat, G., Wali, 
Y.A., and Elbeshalwy, A. (2008). Prenatal diagnosis of beta-Thalassemia in Egypt: 
implementing accurate high-tech methods did not reflect much on the outcome. Pediatr. 
Hematol. Oncol. 25(6), 541-549. 
El-Kalla, S., and Baysal, E. (1998). Alpha-Thalassemia in the United Arab Emirates. Acta. 
Haematol. 100(1), 49-53. 
Felice, E.A., Cleek, P.A., Marino, M.E., Mckie, M.E., Mckie, C.V., Chang, K.A., and Husiman, 
J.H.T. (1986). Different ζ-globin gene deletions among black Americans. Hum. Genet. 173, 
221-224. 
Fucharoen, S.  and Winichagoon, P.  (2011). Haemoglobinopathies in Southeast Asia. Indian J. 
Med. Res. 134, 498-506. 
Fucharoen, S.,  and Viprakasit, V. (2009). Hb H disease: clinical course and disease modifiers. 
Amer. Society Hematol., 26-34. 
 
Giambona, A., Passarello, C., Renda, D., and Maggio, A. (2009). The significance of the 
hemoglobin A (2) value in screening for hemoglobinopathies. Clin. Biochem. 42(18), 1786-
1796. 
Greer, P.J., Foerster, J., Lukens, N.J., Rodgers, G., Paraskvas, F., and Glader, B. (2004) 
Wintrobes’s Clinical Hematology. ( Phiadelphia. A Wolters Kluwer Company).  
Guvenc, B., Yildiz, S.M., Tekinturhan, F., Dincer, S., Akyuzluer, I., Okten, S., and Erkman, H. 
(2010). Molecular characterization of alpha-Thalassemia in Adana, Turkey: A single center 
study. Acta. Haematol. 123(4), 197-200.  
Harteveld, C.L., and Higgs, D.R. (2010). Alpha-thalassaemia. Orphanet J. Rare. Dis. 5, 13. 
  55
Hassan, S.M., Hamza, N., Al-Lawatiya, F.J., Mohammed, A.J, Harteveld , C.L., Rajab, A., and 
Giordano, P.C.(2010). Extended molecular spectrum of beta- and alpha-Thalassemia in Oman. 
Hemoglobin. 34, 127-134. 
Hellani, A., Fadel, E., El-Sadadi, S., El-Sweilam, H., El-Dawood, A., and Abu-Amero, K.K. 
(2009). Molecular spectrum of alpha-Thalassemia mutations in microcytic hypochromic anemia 
patients from Saudi Arabia. Genet. Test. Mol. Biomarkers. 13(2), 219-221. 
Higgs, D.R., Garrick, D., Anguita, E., De Gobbi, M., Hughes, J., Muers, M., Vernimmen, D., 
Lower, K., Law, M., Argentaro, A., et al. (2005) Understanding alpha-globin gene regulation: 
Aiming to improve the management of Thalassemia. Ann. N. Y. Acad. Sci. 1054, 92-102. 
Hossein, F., Mohsen, R., Mohesn, M., and Their, M. (2012). α-Thalassemia mutations in two 
provinces of Southern Iran: Fars & Kohkeloye and Bouyer Ahmad. Hemoglobin. 36(2), 139-
143. 
Khelil, A., Denden, S., Leban, N., Daimi, H., Lakhdhar, R., Leffrac, G., Ben Chibani, D., and 
Perrin, P. (2010). Hemoglobinopathies in North Africa: a review. Hemoglobin. 34(1), 1-23. 
Kohne, E. (2011). Hemoglobinpathies:clinical mainfestations, diagnosis, and treatment. Dtsch. 
Arzteb. Int. 108, (31-32) 532-540. 
Lacerna, G., Musollino, G., Di Noce, F., Prezioso, R., and Carestia, C. (2007). Genotyping for 
known Mediterranean α-Thalassemia point mutations using a multiplex amplification refractory 
mutation system. Haematologica. 92(02), 254-255.  
Liu, Y.T., Old, J.M., Miles, K., Fisher, C.A., Weatherall, D.J. and Clegg, J.B. (2000). Rapid 
detection of α-thalassaemia deletions and α-globin gene triplication by multiplex polymerase 
chain reactions. Br. J. Haematol. 108(2), 295-299. 
Lorey, F., Charoenkwan, P., Witkowska, H.E., Lafferty, J., Patterson, M., Eng, B., Waye, J.S., 
Finklestein, J.Z., and Chui, D.H. (2001). Hb H hydrops foetalis syndrome: a case report and 
review of literature. Br. J. Haematol. 115(1), 72-80. 
  56
Mehdi, S.R., and Al-Dahmash, B.A. (2011). A comparative study of hematological parameter 
of α and β Thalassemia in a high prevalence zone: Saudi Arabia. Indian. J. Hum. Genet. 17(3), 
207-211. 
Mortada, 2009. Aailable at: http://pharamcytimes.wordpress.com/category/human-anatomy-
physiology/page/2/(hemglobin structure). Accessed on December 11, 2012. 
Mosca, A., Paleari, R., Leone, D., and Ivaldi, G. (2009). The relevance of hemoglobin F 
measurement in the diagnosis of Thalassemia and related hemoglobinopathies. Clin. Biochem. 
42(18), 1797-1801. 
Muncie, H.L., and Campbell, J.R. (2009) Alpha and beta Thalassemia. Am. Fam. Physician. 
80(4), 339-344. 
Nelson, D. and Cox, M. (2004). Lehninger Principles of Biochemistry. (W.H.Freeman). 
Ntaios, G., Chatzinikolaou, A., Saouli, Z., Girtovitis, F., Tsapanidou, M., Kaiafa, G., 
Kontoninas, Z., Nikolaidou, A., Savopoulos, C., Pidonia, I. et al. (2007). Discrimination indices 
as screening tests for beta-thalassemic trait. Ann. Hematol. 86 (7), 487–491. 
Old, J.M. (2003). Screening and Genetic diagnosis of Hemoglobin Disorder. Blood Rev. 17(1), 
43-53. 
Oron-Karni, V., Filon, D., Oppenheim , A., and Rund, D. (1998). Rapid Detection of the 
common Mediterranean α-Globin Deletion/ Rearrangement using PCR. Am. J. Hematol. 58(4), 
306-310. 
Oron-Karni, V., Filon, D., Shifrin, Y., Fried, E., Pogrebijsky, G., Oppenheim, A., and Rund, D. 
(2000). Diversity of α-globin mutation and clinical presentation of α-Thalassemia in Israel. Am. 
J. Hematol. 65(3), 196-203. 
Pirastu, M., Lee, Y.K., Dozy, M.A., Kan, Y., Stamatoyanopolus, G., and Hadjiminas, G. 
(1982). Alpha Thalassemia in two Mediterranean population. Blood. 60, 509-512. 
 
  57
Prior, J.F., Bittles, A.H., and  Erber, W.N. (2004). A community profile of alpha thalassaemia 
in Western Australia. Community Genet. 7, 211-215. 
Ribeiro, D.M., and Sonati, M.F. (2008). Regulation of human alpha –globin gene expression 
and alpha Thalassemia. Genet. Mol. Res.7 (4), 1045-1053. 
Rugless, M.J., Fisher, C.A., Stephens, A.D., Amos, R.J., Mohammed, T., and Old, J. (2006). Hb 
Bart’s in cord blood: an accurate indicator of alpha Thalassemia. Hemoglobin. 30(1), 57-62. 
Sae-ung, N., Fucharoen, G., Sanchaisuriya, K., and Fucharoen, S. (2007). α0 Thalassemia and 
related disorder in northeast Thailand: a molecular and hematological characterization. Acta. 
Hematol. 117(2), 78-82. 
Sankar, H.V., Arya, V., Tewari, D., Usha, R., Gupta, R.U., Pradhan, M., and Agarwal, S. 
(2006). Genotyping of alpha-Thalassemia in microcytic hypochromicanemia patients from 
North India. J. Appl. Genet. 47(4), 391–395. 
Sarnaik, S.A. (2005).Thalassemia and related hemoglobinpathies. Indian J. Pediat. 72(4), 319-
324. 
Siala, H., Ouali, F., Messaoud, T., Bibi, A., and Fattoum, S. (2008). Alpha-Thalassaemia in 
Tunisia: some epidemiological and molecular data. J. Genet. 87(3), 229-234. 
Singer, S.T. (2009). Variable clinical phenotypes of a-Thalassemia syndromes. Scientific World 
Journal. 9, 615–625. 
Steensma, D.P., Gibbons, R.J., and Higgs, D.R. (2005). Acquired alpha-Thalassemia in 
association with myelodysplastic syndrome and other hematologic malignancies. Blood. 105, 
443-452. 
Tamaddoni, A., Hadavi, V., Nejan, N.F., Khosh-ani, A., Siami, R., and Aghai-Melbodi, J. 
(2009). α Thalassemia analysis in Mazandaran Province, North Iran. Hemoglobin. 33, 115-123. 
Tan, A.S., Quah, T.C., Low, P.S., and Chong, S.S. (2001). A rapid and reliable 7-deletional 
multiplex polymerase chain reaction assay for α-Thalassemia. Blood. 98(1), 250-251. 
  58
Thakur, S., Ishrie, M., Saxena, R., Danda, S., Linda, R., Viswabandya, A., and Verma, I.C. 
(2011). ATR-X syndrome in two siblings with a novel mutation (c.6718C>T mutation in exon 
31). Indian J. Med. Res. 134, 483-486. 
Tritipsombut, J., Sanchaisuriya, K., Fucharoen, S., Fucharoen, G., Siriratmanawong, N., 
Pinmuang-ngam, C., and Sanchaisuriya, P. (2008). Hemoglobin profiles and hematologic 
features of thalassemic newborns: application to screening of alpha-Thalassemia 1 and 
hemoglobin E. Arch. Pathol. Lab. Med. 132(11), 1739-1744. 
Urbinati, F., Madigan, C., and Malik, P. (2006). Pathopysiology and therapy of 
hemoglobinopathies. Part II: thalassaemias. Expert. Rev. Mol. Med. 8(10), 1-26. 
Vichinsky, E.P. (2005). Changing patterns of Thalassemia worldwide. Ann. N. Y. Acad. Sci. 
1054, 18-24. 
 
Vichinsky, E.P. (2009). Alpha Thalassemia major-new mutations, intrauterine management, 
and outcomes. Hematology Am. Soc. Hematol .Educ. Program .1, 35-41.  
Villegas, A., Porres, A., Sanchez, J., Gonzalez, F.A., Perez-Clausell, C., Martinez, M., Murga, 
M.J., Cacha, J., Lozano, M., Fernandez-Fuertes, I. et.al. (1998). Red blood cell phenotypes in α-
Thalassemia in the Spanish population. Haematologica. 83, 99-103. 
Weatherall, D.J. (1997). The thalassaemias. B. M. J. 314(7095), 1675-1678. 
Weatherall, D.J., and Clegg, J.B. (2001). Inherited haemoglobin disorders: An increasing global 
health problem. Bull. World Health Organ. 79, 704-712. 
Xiong, F., Sun, M., Zhang, X., Cai, R., Zhou, Y., Lou, J., Zeng, L., Sun, Q., Xiao, Q.,  Shang, 
X., et.al. (2010). Molecular epidemiological survey of haemoglobinopathies in the Guangxi 
Zhuang Autonomous Region of southern China. Clin. Genet. 78(2), 139-148. 
Younis, K., Barghuty, F., Abdeen, Z. (1996). Prevalence of β-Thalassemia trait among 
Palestinian students of higher education. Publication of Health Related Research Center at Al-
Quds University-Palestine. 
  59
Zandia, K., Nateghi, J., Keikhaic, B., Pedram, M., Najad, N., Hadavi, V., Oberkanin, C., 
Azarkeivan, A., Law, H., and Najmabadi, H. (2008). α Thalassemia mutation in Khuzestan-
Province South east Iran. Hemoglobin. 32(6), 546–552. 
Zorai, A., Harteveld, C.L., Bakir, A., Van Delft, P., Falfoul, A., Dellagi, K., Abbes, S., and 
Giordano, P.C. (2002). Molecular spectrum of alpha-Thalassemia in Tunisia: epidemiology and 
detection at birth. Hemoglobin. 26(4), 353-362. 
Zuysal, Z., Yildirmark, Y., Akar, N., Basak, N., and Cis, S. (1998). Alpha-Thalassemia and 
hereditary spherocytosis in the same patient: the interaction of two diseases. Pediatr. Hematol. 
Oncol. 15(3), 271-277. 
Appendix A 
 
Table A.1: Hematological parameters for the study samples. 
Sample 
# 
RBCs 
(x10
6
/µL) 
Hb 
(g/dL) 
MCV 
(fL)  
MCH  
(pg/cell) 
RDW% 
 
HbA2 
(%) 
MI 
Patients samples 
1 4.9 9.2 63.3 18.9 20.2 2.1 12.9 
2 5.0 9.5 59.2 19.1 23.2 2.1 11.8 
3 4.6 8.6 58.6 18.8 15.7 3.0 12.7 
4 4.5 7.9 58.3 17.7 17.4 2.0 13.0 
5 4.6 8.9 59.4 19.2 19.4 3.4 12.9 
6 4.9 9.0 57.9 18.4 16.8 2.5 11.8 
7 4.9 9.0 58.1 18.3 17.8 1.8 11.8 
8 4.9 10.0 60.2 20.3 16.1 3.0 12.2 
9 4.9 10.0 61.8 20.3 17.7 3.0 12.6 
10 4.6 8.8 56.5 19.0 19.0 1.5 12.3 
11 4.9 8.5 57.4 17.3 19.0 2.2 11.7 
12 5.0 10.7 62.5 21.6 21.4 2.0 12.5 
13 4.9 10.1 63.8 20.6 18.9 2.9 13.0 
14 5.0 10.6 68.1 21.3 15.5 2.4 13.6 
15 4.7 5.7 47.0 12.1 19.6 1.5 10.0 
16 5.2 17.3 76.1 24.8 13.6 2.4 14.6 
17 5.3 11.3 64.8 21.2 16.0 3.0 12.2 
18 5.1 8.6 58.4 17.0 20.0 2.4 11.5 
19 5.4 9.2 57.9 17.2 22.6 2.1 10.7 
20 5.6 12.8 72.6 22.7 14.4 3.2 13.0 
21 5.9 11.4 60.7 19.4 15.8 2.2 10.3 
22 5.1 7.5 56.6 14.7 21.7 2.5 11.1 
23 6.0 14.1 72.4 23.7 14.1 2.5 12.1 
24 6.0 9.0 72.4 23.7 18.4 2.5 12.1 
25 5.2 9.3 56.7 17.8 18.1 2.5 10.9 
26 5.8 14.5 73.8 25.2 14.1 2.6 12.7 
27 5.6 11.7 62.4 20.9 19.7 2.5 11.1 
28 5.3 12.7 68.8 24.2 14.5 2.8 13.0 
29 5.5 10.2 56.2 18.6 18.5 3.2 10.2 
30 5.1 9.2 63.1 18.2 22.2 2.9 12.4 
31 5.7 11.9 65.6 21.0 15.6 3.0 11.5 
32 5.8 11.0 56.6 18.9 14.4 2.2 9.8 
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Table A.1: cont. 
Sample 
# 
RBCs 
(x1012/L) 
Hb 
(g/dL) 
MCV 
(fL)  
MCH  
(pg/cell) 
RDW 
 
HbA2 
(%) 
MI 
33 5.2 8.9 59.9 17.2 23.0 2.7 11.5 
34 5.0 11.0 62.4 21.0 15.9 2.9 12.5 
35 5.1 8.7 57.5 17.1 21.0 2.0 11.3 
36 5.4 10.7 58.9 19.7 22.6 2.0 10.9 
37 5.6 9.4 59.0 16.8 21.5 2.3 10.5 
38 5.4 12.5 70.6 23.3 17.4 2.7 13.1 
39 5.3 11.9 68.5 22.4 16.5 2.5 12.9 
40 5.2 9.4 58.5 18.2 19.6 2.5 11.2 
41 5.6 13.0 68.9 23.0 14.3 3.0 12.3 
42 5.8 14.8 75.5 25.8 14.5 2.8 13.0 
43 5.2 11.6 66.7 22.5 16.9 3.5 12.8 
44 5.3 9.7 57.1 18.4 20.4 1.5 10.8 
45 5.8 11.0 61.2 19.1 17.2 2.6 10.6 
46 5.8 14.0 75.8 24.3 13.8 2.5 13.1 
47 5.9 11.1 61.6 19.5 18.8      2.6 10.4 
48 5.8 13.4 73.3 23.2 13.9 3.0 12.6 
49 5.5 11.0 58.9 20.0 17.9 3.5 10.7 
50 5.7 10.4 58.7 18.3 17.0      2.6 10.3 
51 5.6 12.8 75.5 22.8 14.9 2.8 13.5 
52 5.3 11.9 65.2 22.8 15.7 3.0 12.3 
53 5.5 10.2 55.9 18.6 15.0 2.3 10.2 
54 5.6 14.0 76.6 24.8 13.3 3.0 13.6 
55 5.5 16.9 79.9 25.8 13.9 2.6 14.5 
56 5.7 11.4 74.5 20.0 17.7 3.0 13.1 
57 5.7 15.6 77.2 27.1 13.0 2.6 13.5 
58 6.2 15.0 74.8 24.2 14.2 2.8 12.1 
59 6.3 13.3 64.1 21.1 16.0 2.5 10.2 
60 6.2 11.0 52.2 17.8 20.8 2.6 8.4 
61 6.6 16.6 74.0 25.0 22.6 3.0 11.2 
62 6.1 14.6 74.0 24.1 14.5 3.0 12.1 
63 6.3 15.6 73.1 24.8 12.9 2.6 11.6 
64 6.4 16.1 74.4 25.3 12.5 2.5 11.6 
65 6.2 12.9 64.7 20.7 15.5 2.8 10.4 
66 6.2 16.7 77.2 27.0 13.5 3.0 12.5 
67 6.4 14.5 67.6 22.6 14.5 2.9 10.6 
68 6.5 14.8 66.5 22.7 14.5 3.0 10.2 
69 6.0 16.0 77.4 26.6 12.5 2.8 12.9 
70 6.5 14.8 68.3 22.9 13.7 2.4 10.5 
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Table A.1: cont. 
Sample 
# 
RBCs 
(x1012/L) 
Hb 
(g/dL) 
MCV 
(fL)  
MCH  
(pg/cell) 
RDW 
 
HbA2 
(%) 
MI 
71 6.4 13.3 66.9 20.8 16.6 2.8 10.4 
72 6.2 15.7 75.7 25.2 14.6     2.6 12.2 
73 6.2 14.8 72.0 24.0 15.7 2.8 11.6 
Neonatal samples 
1 4.0 12.0 90.8 30.0 27.5 ND - 
2 4.9 13.9 86.0 28.5 15.0 ND - 
3 3.3 10.6 93.7 32.4 15.0 ND - 
4 4.2 14.6 93.2 32.7 18.8 ND - 
5 4.3 14.6 93.8 33.4 15.8     ND - 
6 4.6 14.2 87.6 30.9 15.7 ND - 
7 4.3 14.2 93.3 32.9 16.5      ND - 
8 4.8 16.3 93.5 34.0 15.4     ND - 
9 4.9 16.1 93.0 32.9 16.8 ND - 
10 4.85 15.8 94.3 32.6 18.9     ND  - 
11 5.9 18.4 88.8 31.0 15.3 ND - 
12 5.7 18.0 87.2 31.7 14.6 ND - 
13 5.7 18.2 87.7 32.0 29.4     ND  - 
14 5.3 13.5 91.1 22.4 16.2 ND - 
15 6.3 20.9 93.9 33.4 16.4 ND - 
16 5.7 18.1 91.1 32.0 15.0 ND - 
17 4.8 14.3 94.9 29.7 15.5 ND - 
18 5.26 17.0 93.2 32.3 18.3 ND - 
19 4.21 12.3 93.3 29.2 12.3 ND - 
ND: not determined. 
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ﺼﻐﺭ ﻏﻴﺭ ﻤﺒﺭﺭ ﻤﻥ ﻥ ﺍﻝﺫﻴﻥ ﻴﻌﺎﻨﻭﻥ ﻨﻴﻴﻴﻥ ﺠﻴﻥ ﺒﻴﻥ ﺍﻝﻤﺭﻀﻰ ﺍﻝﻔﻠﺴﻁ ﺠﻠﻭﺒ-ﻨﻭﻉ ﺍﻝﻁﻔﺭﺓ ﻓﻲ ﺍﻝﻔﺎﺘﺤﺩﻴﺩ 
  ﻓﻲ ﺤﺠﻡ ﻜﺭﻴﺎﺕ ﺍﻝﺩﻡ ﺍﻝﺤﻤﺭﺍﺀ
  
  ﻤﻴﺴﻭﻥ ﻋﺩﻨﺎﻥ ﺴﻠﻴﻤﺎﻥ ﺤﻤﺎﻴل: ﺍﻋﺩﺍﺩ
  
  ﻤﺤﻤﻭﺩ ﺴﺭﻭﺭ .ﺩ: ﺍﻝﻤﺸﺭﻑ ﺍﻻﻭل
  ﺨﺎﻝﺩ ﻴﻭﻨﺱ.ﺃ: ﺍﻝﻤﺸﺭﻑ ﺍﻝﺜﺎﻨﻲ
 
 ﻭﻨﻘﺹ ﻓﻲ  ﺍﻝﺤﻤﺭﺍﺀ ﺍﻝﺩﻡﺎﺕﺒﻔﻘﺭ ﺩﻡ ﻤﺼﺎﺤﺏ ﻝﻪ ﺼﻐﺭ ﻓﻲ ﺤﺠﻡ ﻜﺭﻴﺜﻼﺴﻤﻴﺎ ﻫﻭ ﻤﺭﺽ ﻭﺭﺍﺜﻲ ﻤﺘﻨﺤﻲ ﺍﻝﺼﻔﺔ ﻴﺘﻤﻴﺯ -ﺃﻝﻔﺎ
ﻭﻫﻭ ﻤﺭﺽ ﺸﺎﺌﻊ ﻓﻲ ﺍﻝﻌﺎﻝﻡ . ﺘﺘﺭﺍﻭﺡ ﻤﺎ ﺒﻴﻥ ﺤﺎﻤل ﻝﻠﻤﺭﺽ ﺒﺩﻭﻥ ﺃﻋﺭﺍﺽ ﺍﻝﻰ ﻤﺭﺽ ﻗﺎﺘلﻓ ﺍﻤﺎ ﺃﻋﺭﺍﻀﻪ .ﺘﺼﺒﻐﻬﺎ
 .ﻭﺨﺼﻭﺼﺎ ﻓﻲ ﻤﻨﻁﻘﺔ ﺤﻭﺽ ﺍﻝﺒﺤﺭ ﺍﻻﺒﻴﺽ ﺍﻝﻤﺘﻭﺴﻁ ﻭﺍﻝﺸﺭﻕ ﺍﻻﻭﺴﻁ ﻭﺸﺭﻕ ﺍﺴﻴﺎ ﻭﺍﻓﺭﻴﻘﻴﺎ ﻭﺸﺒﻪ ﺍﻝﻘﺎﺭﺓ ﺍﻝﻬﻨﺩﻴﺔ
. ﻕ ﻓﻲ ﺤﻭﺽ ﺍﻝﺒﺤﺭ ﺍﻻﺒﻴﺽ ﺍﻝﻤﺘﻭﺴﻁ ﻭﻝﻜﻥ ﻝﻴﺱ ﻓﻲ ﻓﻠﺴﻁﻴﻥﺍﻻﺴﺒﺎﺏ ﺍﻝﻭﺭﺍﺜﻴﺔ ﻝﻬﺫﺍ ﺍﻝﻤﺭﺽ ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﺎ ﻓﻲ ﻋﺩﺓ ﻤﻨﺎﻁ
(-α37./, –α42./  ,α2-ISVI-5tn ,--DEM/  ﺘﻬﺩﻑ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﺍﻝﻰ ﺘﺤﺩﻴﺩ ﻨﺴﺒﺔ ﻭﻨﻭﻉ ﺍﻝﺨﻠل ﺍﻝﻭﺭﺍﺜﻲ ﻓﻲ ﺍﻝﻔﺎ ﺠﻠﻭﺒﻴﻥ ﺠﻴﻥ
.  ﻝﺴﺒﺏ ﻏﻴﺭ ﻭﺍﻀﺢ ﺍﻝﺤﻤﺭﺍﺀ ﺍﻝﺩﻡﺎﺕ ﺍﻝﺫﻴﻥ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺼﻐﺭ ﻓﻲ ﺤﺠﻡ ﻜﺭﻴ ﺍﻝﻤﺭﻀﻰﻤﺠﻤﻭﻋﺔ ﻤﻥ  ﻓﻲ )7.3itnaααα dna
  ﺍﻝﺩﻡﺎﺕ ﻋﻴﻨﺔ ﻤﻥ ﻫﺅﻻﺀ ﺍﻝﻤﺭﻀﻰ ﺒﻌﺩ ﺍﻥ ﺘﻡ ﺍﺴﺘﺒﻌﺎﺩ ﺍﻥ ﻴﻜﻭﻥ ﺍﻝﺴﺒﺏ ﻓﻲ ﺼﻐﺭ ﺤﺠﻡ ﻜﺭﻴ37ﻤﻥ ﺍﺠل ﺫﻝﻙ ﺘﻡ ﺠﻤﻊ 
 ﻋﻴﻨﺔ ﻻﻁﻔﺎل 91ﺒﺎﻻﻀﺎﻓﺔ ﺍﻝﻰ ﻫﺅﻻﺀ ﺍﻝﻤﺭﻀﻰ ﺘﻡ ﺘﺠﻤﻴﻊ . ﻨﻘﺹ ﺍﻝﺤﺩﻴﺩﻓﻘﺭ ﺩﻡ ﻨﺎﺘﺞ ﻋﻥ  ﺜﻼﺴﻤﻴﺎ ﺍﻭ -  ﻫﻭ ﺒﻴﺕﺍﻝﺤﻤﺭﺍﺀ
ﺘﻡ ﺍﺴﺘﺨﺩﺍﻡ ﻋﺩﺓ ﻁﺭﻕ . )Lf 59(ﺘﻭﻝﻴﺘﺭﻤ ﻓﻴ59 ﻤﻥ  ﻝﺩﻴﻬﻡ ﺍﻗل ﺍﻝﺤﻤﺭﺍﺀ ﺍﻝﺩﻡﺎﺕﺤﺠﻡ ﻜﺭﻴﺒﺤﻴﺙ ﻴﻜﺯﻥ ﺤﺩﻴﺜﻲ ﺍﻝﻭﻻﺩﺓ 
 SMRA ,gnicneuqes AND ,RCP-paGﺜﻼﺴﻤﻴﺎ ﻓﻲ ﻫﺅﻻﺀ ﺍﻝﻤﺭﻀﻰ ﻭﻫﻲ - ﻝﻠﻜﺸﻑ ﻋﻥ ﺍﻝﻁﻔﺭﺍﺕ ﺍﻝﻤﺴﺒﺒﺔ  ﻻﻝﻔﺎ
  .RCP
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-- ﺍﻭ tn5-ISVI-2α ﺍﻭα7.3ﺤﺎﻤﻠﻴﻥ ﻻﺤﺩﻯ ﻫﺫﻩ ﺍﻝﻁﻔﺭﺍﺕ % 7.05ﻜﺎﻥ ﻫﻨﺎﻙ ,  ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﻡ ﻤﺭﻴﺽ37  ﺒﻴﻥ ﻤﻥ
 % 9.84ﺒﺎﻝﻨﺴﺏ ﺍﻻﺘﻴﺔ ﻭ tn5-ISVI-2α  ﻭ α7.3ﺜﺭ ﻫﺫﻩ ﺍﻝﻁﻔﺭﺍﺕ ﺸﻴﻭﻋﺎ ﺒﻴﻥ ﺍﻝﻤﺭﻀﻰ ﻜﺎﻥ ﺃﻜ .ααα 7.3 itna ﺍﻭDEM
ﻓﻲ . ﺒﺎﻝﺘﺭﺘﻴﺏ%  1.2ﻭ%  3.4ﻜﺎﻨﺕ ﻤﻭﺠﻭﺩﺓ ﺒﺎﻝﻨﺴﺏ ﺍﻻﺘﻴﻪ ﻓﻘﺩ   ααα7.3 itna ﻭ DEM--ﺍﻤﺎ  .ﺒﺎﻝﺘﺭﺘﻴﺏ%  7.44ﻭ
ﺍﻝﻁﻔﺭﺓ ﺍﻝﻤﺴﺒﺒﺔ . ﻜﺜﺭ ﺸﻴﻭﻋﺎ ﺍﻻ ﻫﻲﺍﻴﻀﺎ tn5-ISVI-2α ,7.3α() ﺍﻝﻁﻔﺭﺍﺕ ﺍﻝﺘﺎﻝﻴﺔ ﻜﺎﻨﺕﻋﻴﻨﺎﺕ ﺍﻻﻁﻔﺎل ﺤﺩﻴﺜﻲ ﺍﻝﻭﻻﺩﺓ 
ﻤﻨﻁﻘﺔ ﻷﻥ ﻫﺫﻩ ﺍﻝﻁﻔﺭﺓ ﺘﺘﻭﺍﺠﺩ ﺒﺎﻝﻨﺴﺒﺔ ﻀﺌﻴﻠﺔ ﻓﻲ . ﻝﻡ ﻴﺘﻡ ﺍﻴﺠﺎﺩﻫﺎ ﻓﻲ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﺒﻴﻥ ﻫﺅﻻﺀ ﺍﻝﻤﺭﻀﻰα2.4ﺜﻼﺴﻤﻴﺎ - ﻻﻝﻔﺎ
 ﺒﻌﺩ ﻁﻔﺭﺓ ﻫﻲ ﺍﻝﻁﻔﺭﺓ ﺍﻝﺜﺎﻨﻴﺔ ﺍﻻﻜﺜﺭ ﺸﻴﻭﻋﺎ ﺒﻴﻥ ﻫﺅﻻﺀ ﺍﻝﻤﺭﻀﻰ tn5-ISVI-2αﻁﻔﺭﺓ  .ﺍﻻﺒﻴﺽ ﺍﻝﻤﺘﻭﺴﻁﺍﻝﺒﺤﺭ ﺤﻭﺽ 
 ﺍﻝﺩﻡ ﺍﻝﺤﻤﺭﺍﺀ ﻭﻨﻭﻉ ﺍﻝﻁﻔﺭﺓ ﻝﻡ ﻜﺭﻴﺎﺕ ﻓﻲ ﺘﺤﻠﻴل ﺍﻝﻌﻼﻗﺔ ﺒﻴﻥ ﻗﻴﺎﺴﺎﺕ . ﻓﻲ ﺃﻱ ﻤﺠﺘﻤﻊ ﺁﺨﺭﺸﺭﻩ ﻤﻥ ﻗﺒلﻭﻫﺫﺍ ﻝﻡ ﻴﺘﻡ ﻨ. 7.3α
 ﻭﻋﻠﻴﻪ ﻓﺎﻥ .ﺜﻼﺴﻤﻴﺎ- ﺍﻝﻜﺸﻑ ﻋﻥ ﻭﺠﻭﺩ ﺍﻝﻔﺎ ﻫﺫﻩ ﺍﻝﻘﻴﺎﺴﺎﺕ ﺘﺴﺘﻁﻴﻊ ﺒﻴﻨﻬﻤﺎ ﻭﺒﺎﻝﺘﺎﻝﻲ ﻻ  ﺫﺍﺕ ﺩﻻﻝﺔ ﺍﺤﺼﺎﺌﻴﺔﻗﺔﻴﺘﻡ ﺍﻴﺠﺎﺩ ﻋﻼ
  .ﻼﺴﻤﻴﺎﺜ-ﺍﻝﺘﺸﺨﻴﺹ ﺍﻝﺠﺯﻴﺌﻲ ﻫﻭ ﺍﻻﻜﺜﺭ ﺩﻗﺔ ﻭﺍﻋﺘﻤﺎﺩﺍ ﻝﻠﻜﺸﻑ ﻋﻥ ﺍﻝﻔﺎ
  
  ﺍﻝﺤﻤﺭﺍﺀ ﺍﻝﺩﻡﺎﺕ ﻤﻥ ﻋﻴﻨﺎﺕ ﺍﻝﻤﺭﻀﻰ ﺍﻝﺫﻴﻥ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺼﻐﺭ ﺤﺠﻡ ﻜﺭﻴ%( 7.05 ) ﻨﺴﺒﺔ ﻜﺒﻴﺭﺓ ﻥﻓﺎﺨﻼﺼﺔ ﺍﻝﻭﻓﻲ 
 ﺍﻝﺠﺯﻴﺌﻲ ﻀﺭﻭﺭﻱ ﺠﺩﺍ  ﺍﻝﺘﺸﺨﻴﺹ ﻜﻤﺎ ﺍﻥ.ﺜﻼﺴﻤﻴﺎ- ﻔﺎﻤﻠﻴﻥ ﻻﺤﺩﻯ ﺍﻝﻁﻔﺭﺍﺕ ﺍﻝﻤﺴﺒﺒﺔ ﻷﻝ ﻜﺎﻨﻭﺍ ﺤﺎ ﻝﺴﺒﺏ ﻏﻴﺭ ﻭﺍﻀﺢ
  .ﻰﻝﻬﺅﻻﺀ ﺍﻝﻤﺭﻀ
 
